Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

ABSTRACT

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington&#39;s disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

This application is a divisional of U.S. patent application Ser. No.13/056.305, filed Jan. 27, 2011, which is a national phase applicationunder 35 U.S.C. §371 of Patent Cooperation Treaty Application No.PCT/US2009/052667, filed Aug. 4, 2009, which claims priority to U.S.Provisional Application No. 61/086,090, filed Aug. 4, 2008, each ofwhich is incorporated herein by reference.

Provided herein are certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions thereof, and methods of their use.

Kynurenine-3-monooxygenase (KMO) is an enzyme in the tryptophandegradation pathway that catalyzes the conversion of kynurenine into3-hydroxykynurenine (3-HK), which is a precursor of the neurotoxinquinolinic acid (QUIN). Therefore, compounds which act as inhibitors ofKMO are of particular interest since they may block the metabolismtoward QUIN and at the same time, may increase the formation ofneuroprotective metabolite kynurenic acid (KYNA).

KMO inhibitors have been proposed as therapeutic agents for thetreatment of neurodegenerative disease such Huntington's disease,Alzheimer's disease, dementia caused by Acquired ImmunodeficiencySyndrome (AIDS), infarctual dementia, cerebral ischemia, cerebralhypoxia, Parkinson's disease, epilepsy, head and spinal cord injury,amyotrophic lateral sclerosis, glaucoma retinopathy, infections of thebrain or inflammations of the brain. There remains a need for compoundsthat are effective inhibitors of KMO and may be used in treatingneurodegenerative disorders.

Provided is at least one chemical entity chosen from compounds ofFormula I

and pharmaceutically acceptable salts and prodrugs thereof wherein:

-   X and Y are independently chosen from CH and N provided that at    least one of X and Y is N;-   R₁ is chosen from aryl and heteroaryl, each of which is substituted    with one, two, or three groups chosen from halo, optionally    substituted lower alkyl, lower alkoxy, optionally substituted amino,    optionally substituted heterocycloalkyl, optionally substituted    heteroaryl, and hydroxy;-   L is chosen from —C(O)O—, —C(O)N(R₃)—, —N(R₃)C(O)—, —N(R₃)S(O)₂—,    and —S(O)₂N(R₃)—;-   R₂ is chosen from hydrogen, optionally substituted lower alkyl,    optionally substituted aryl, optionally substituted heteroaryl,    optionally substituted cycloalkyl, and optionally substituted    heterocycloalkyl, provided that when L is —N(R₃)S(O)₂—, R₂ is not    hydrogen;-   R₃ is chosen from hydrogen and lower alkyl; or-   R₂ and R₃, taken together with any intervening atoms, forms an    optionally substituted heterocycloalkyl ring;-   R₄ is chosen from hydrogen and optionally substituted lower alkyl;    and-   R₅ is chosen from hydrogen and fluoro,-   provided that the compound of Formula I is not-   N-(1-hydroxy-3-(1H-indol-3-yl)propan-2-yl)-6-(4-methoxyphenyl)pyrimidine-4-carboxamide;-   3-chloro-2-methyl-N-(6-phenylpyrimidin-4-yl)benzenesulfonamide;-   4-methoxy-N-(6-phenylpyrimidin-4-yl)benzamide;-   N-(6-phenylpyrimidin-4-yl)benzamide;-   6-phenylpyrimidine-4-carboxylic acid;-   methyl 6-phenylpyrimidine-4-carboxylate;-   ethyl 6-phenylpyrimidine-4-carboxylate;-   6-phenylpyrimidine-4-carboxamide;-   N-methyl-6-phenylpyrimidine-4-carboxamide; or-   N,N-dimethyl-6-phenylpyrimidine-4-carboxamide.

Also provided is a pharmaceutical composition comprising at least onechemical entity described herein and at least one pharmaceuticallyacceptable excipient.

Also provided is a packaged pharmaceutical composition comprising atleast one pharmaceutical composition described herein and instructionsfor using the composition to treat a subject suffering from a conditionor disorder mediated by Kynurenine 3-mono-oxygenase activity.

Also provided is a method of treating a condition or disorder mediatedby Kynurenine 3-mono-oxygenase activity in a subject in need of such atreatment which method comprises administering to the subject atherapeutically effective amount of at least one chemical entitydescribed herein.

As used in the present specification, the following words, phrases andsymbols are generally intended to have the meanings as set forth below,except to the extent that the context in which they are used indicatesotherwise. The following abbreviations and terms have the indicatedmeanings throughout:

A dash (“-”) that is not between two letters or symbols is used toindicate a point of attachment for a substituent. For example, —CONH₂ isattached through the carbon atom.

By “optional” or “optionally” is meant that the subsequently describedevent or circumstance may or may not occur, and that the descriptionincludes instances where the event or circumstance occurs and instancesin which it does not. For example, “optionally substituted alkyl”encompasses both “alkyl” and “substituted alkyl” as defined below. Itwill be understood by those skilled in the art, with respect to anygroup containing one or more substituents, that such groups are notintended to introduce any substitution or substitution patterns that aresterically impractical, synthetically non-feasible and/or inherentlyunstable.

“Alkyl” encompasses straight chain and branched chain having theindicated number of carbon atoms, usually from 1 to 20 carbon atoms, forexample 1 to 8 carbon atoms, such as 1 to 6 carbon atoms. For exampleC₁-C₆ alkyl encompasses both straight and branched chain alkyl of from 1to 6 carbon atoms. Examples of alkyl groups include methyl, ethyl,propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl,isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, and thelike. Alkylene is another subset of alkyl, referring to the sameresidues as alkyl, but having two points of attachment. Alkylene groupswill usually have from 2 to 20 carbon atoms, for example 2 to 8 carbonatoms, such as from 2 to 6 carbon atoms. For example, C₀ alkyleneindicates a covalent bond and C₁ alkylene is a methylene group. When analkyl residue having a specific number of carbons is named, allgeometric isomers having that number of carbons are intended to beencompassed; thus, for example, “butyl” is meant to include n-butyl,sec-butyl, isobutyl and t-butyl; “propyl” includes n-propyl andisopropyl. “Lower alkyl” refers to alkyl groups having 1 to 4 carbons.

“Cycloalkyl” indicates a saturated hydrocarbon ring group, having thespecified number of carbon atoms, usually from 3 to 7 ring carbon atoms.Examples of cycloalkyl groups include cyclopropyl, cyclobutyl,cyclopentyl, and cyclohexyl as well as bridged and caged saturated ringgroups such as norbornane.

By “alkoxy” is meant an alkyl group of the indicated number of carbonatoms attached through an oxygen bridge such as, for example, methoxy,ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy,2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy,3-methylpentoxy, and the like. Alkoxy groups will usually have from 1 to6 carbon atoms attached through the oxygen bridge. “Lower alkoxy” refersto alkoxy groups having 1 to 4 carbons.

“Aryl” encompasses:

-   -   5- and 6-membered carbocyclic aromatic rings, for example,        benzene;    -   bicyclic ring systems wherein at least one ring is carbocyclic        and aromatic, for example, naphthalene, indane, and tetralin;        and    -   tricyclic ring systems wherein at least one ring is carbocyclic        and aromatic, for example, fluorene.        For example, aryl includes 5- and 6-membered carbocyclic        aromatic rings fused to a 5- to 7-membered heterocycloalkyl ring        containing 1 or more heteroatoms chosen from N, O, and S,        provided that the point of attachment is at the carbocyclic        aromatic ring. Bivalent radicals formed from substituted benzene        derivatives and having the free valences at ring atoms are named        as substituted phenylene radicals. Bivalent radicals derived        from univalent polycyclic hydrocarbon radicals whose names end        in “-yl” by removal of one hydrogen atom from the carbon atom        with the free valence are named by adding “-idene” to the name        of the corresponding univalent radical, e.g., a naphthyl group        with two points of attachment is termed naphthylidene. Aryl,        however, does not encompass or overlap in any way with        heteroaryl, separately defined below. Hence, if one or more        carbocyclic aromatic rings is fused with a heterocycloalkyl        aromatic ring, the resulting ring system is heteroaryl, not        aryl, as defined herein.

The term “halo” includes fluoro, chloro, bromo, and iodo, and the term“halogen” includes fluorine, chlorine, bromine, and iodine.

“Heteroaryl” encompasses:

-   -   5- to 7-membered aromatic, monocyclic rings containing one or        more, for example, from 1 to 4, or In some embodiments, from 1        to 3, heteroatoms chosen from N, O, and S, with the remaining        ring atoms being carbon; and    -   bicyclic heterocycloalkyl rings containing one or more, for        example, from 1 to 4, or In some embodiments, from 1 to 3,        heteroatoms chosen from N, O, and S, with the remaining ring        atoms being carbon and wherein at least one heteroatom is        present in an aromatic ring.        For example, heteroaryl includes a 5- to 7-membered        heterocycloalkyl, aromatic ring fused to a 5- to 7-membered        cycloalkyl ring. For example, heteroaryl also includes a 5- or        6-membered heterocycloalkyl, aromatic ring fused to a 5- to        7-membered aryl ring. For such fused, bicyclic heteroaryl ring        systems wherein only one of the rings contains one or more        heteroatoms, the point of attachment may be at the        heteroaromatic ring or the cycloalkyl ring. When the total        number of S and O atoms in the heteroaryl group exceeds 1, those        heteroatoms are not adjacent to one another. In some        embodiments, the total number of S and O atoms in the heteroaryl        group is not more than 2. In some embodiments, the total number        of S and O atoms in the aromatic heterocycle is not more than 1.        Examples of heteroaryl groups include, but are not limited to,        (as numbered from the linkage position assigned priority 1),        2-pyridyl, 3-pyridyl, 4-pyridyl, 2,3-pyrazinyl, 3,4-pyrazinyl,        2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,3-pyrazolinyl,        2,4-imidazolinyl, isoxazolinyl, oxazolinyl, thiazolinyl,        thiadiazolinyl, tetrazolyl, thienyl, benzothiophenyl, furanyl,        benzofuranyl, benzoimidazolinyl, indolinyl, pyridizinyl,        triazolyl, quinolinyl, pyrazolyl, and        5,6,7,8-tetrahydroisoquinoline. Bivalent radicals derived from        univalent heteroaryl radicals whose names end in “-yl” by        removal of one hydrogen atom from the atom with the free valence        are named by adding “-idene” to the name of the corresponding        univalent radical, e.g., a pyridyl group with two points of        attachment is a pyridylidene. Heteroaryl does not encompass or        overlap with aryl as defined above.

Substituted heteroaryl also includes ring systems substituted with oneor more oxide (—O⁻) substituents, such as pyridinyl N-oxides.

By “heterocycloalkyl” is meant a single aliphatic ring, usually with 3to 7 ring atoms, containing at least 2 carbon atoms in addition to 1-3heteroatoms independently selected from oxygen, sulfur, and nitrogen, aswell as combinations comprising at least one of the foregoingheteroatoms. “Heterocycloalkyl” also refers to 5- and 6-memberedcarbocyclic aromatic rings fused to a 5- to 7-membered heterocycloalkylring containing 1 or more heteroatoms chosen from N, O, and S, providedthat the point of attachment is at the heterocycloalkyl ring. Suitableheterocycloalkyl groups include, for example (as numbered from thelinkage position assigned priority 1), 2-pyrrolidinyl,2,4-imidazolidinyl, 2,3-pyrazolidinyl, 2-piperidinyl, 3-piperidinyl,4-piperidinyl, and 2,5-piperazinyl. Morpholinyl groups are alsocontemplated, including 2-morpholinyl and 3-morpholinyl (numberedwherein the oxygen is assigned priority 1). Substituted heterocycloalkylalso includes ring systems substituted with one or more oxo moieties,such as piperidinyl N-oxide, morpholinyl-N-oxide,1-oxo-1-thiomorpholinyl and 1,1-dioxo-1-thiomorpholinyl.

The term “substituted”, as used herein, means that any one or morehydrogens on the designated atom or group is replaced with a selectionfrom the indicated group, provided that the designated atom's normalvalence is not exceeded. When a substituent is oxo (i.e., ═O) then 2hydrogens on the atom are replaced. Combinations of substituents and/orvariables are permissible only if such combinations result in stablecompounds or useful synthetic intermediates. A stable compound or stablestructure is meant to imply a compound that is sufficiently robust tosurvive isolation from a reaction mixture, and subsequent formulation asan agent having at least practical utility. Unless otherwise specified,substituents are named into the core structure. For example, it is to beunderstood that when (cycloalkyl)alkyl is listed as a possiblesubstituent, the point of attachment of this substituent to the corestructure is in the alkyl portion.

The terms “substituted” alkyl (including without limitation loweralkyl), cycloalkyl, aryl (including without limitation phenyl),heterocycloalkyl (including without limitation morpholin-4-yl,3,4-dihydroquinolin-1(2H)-yl, indolin-1-yl, 3-oxopiperazin-1-yl,piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, azetidin-1-yl, andisoindolin-2-yl), and heteroaryl (including without limitationpyridinyl), unless otherwise expressly defined, refer respectively toalkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl wherein one ormore (such as up to 5, for example, up to 3) hydrogen atoms are replacedby a substituent independently chosen from:

—R^(a), —OR^(b), —O(C₁-C₂ alkyl)O— (e.g., methylenedioxy-), —SR″,guanidine, guanidine wherein one or more of the guanidine hydrogens arereplaced with a lower-alkyl group, —NR^(b)R^(c), halo, cyano, oxo (as asubstituent for heterocycloalkyl), nitro, —COR^(b), —CO₂R^(b),—CONR^(b)R^(c), —OCOR^(b), —OCO₂R^(a), —OCONR^(b)R^(c), —NR^(c)COR^(b),—NR^(c)CO₂R^(a), —NR^(c)CONR^(b)R^(c), —SOR^(a), —SO₂R^(a),—SO₂NR^(b)R^(c), and —NR^(c)SO₂R^(a),

where R^(a) is chosen from optionally substituted C₁-C₆ alkyl,optionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heterocycloalkyl, and optionally substitutedheteroaryl;

R^(b) is chosen from H, optionally substituted C₁-C₆ alkyl, optionallysubstituted aryl, and optionally substituted heteroaryl; and

R^(c) is chosen from hydrogen and optionally substituted C₁-C₄ alkyl; or

R^(b) and R^(c), and the nitrogen to which they are attached, form anoptionally substituted heterocycloalkyl group; and

where each optionally substituted group is unsubstituted orindependently substituted with one or more, such as one, two, or three,substituents independently selected from C₁-C₄ alkyl, C₃-C₆ cycloalkyl,aryl, heteroaryl, aryl-C₁-C₄ alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄haloalkyl-, —OC₁-C₄ alkyl, —OC₁-C₄ alkylphenyl, —C₁-C₄ alkyl-OH, —C₁-C₄alkyl-O—C₁-C₄ alkyl, —OC₁-C₄ haloalkyl, halo, —OH, —NH₂, —C₁-C₄alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄ alkyl), —N(C₁-C₄alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl), cyano, nitro, oxo (asa substitutent for heteroaryl), —CO₂H, —C(O)OC₁-C₄ alkyl, —CON(C₁-C₄alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl), —CONH₂, —NHC(O)(C₁-C₄ alkyl),—NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl), —N(C₁-C₄alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ phenyl, —C(O)C₁-C₄haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl), —SO₂(phenyl),—SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —SO₂NH(C₁-C₄ alkyl), —SO₂NH(phenyl),—NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), and —NHSO₂(C₁-C₄ haloalkyl).

The term “substituted alkoxy” refers to alkoxy wherein the alkylconstituent is substituted (i.e., —O-(substituted alkyl)) wherein“substituted alkyl” is as described herein. “Substituted alkoxy” alsoincludes glycosides (i.e., glycosyl groups) and derivatives of ascorbicacid.

The term “substituted amino” refers to the group —NHR^(d) or—NR^(d)R^(d) where each R^(d) is independently chosen from: hydroxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted acyl, aminocarbonyl, optionally substituted aryl,optionally substituted heteroaryl, optionally substitutedheterocycloalkyl, optionally substituted alkoxycarbonyl, sulfinyl andsulfonyl, each as described herein, and provided that only one R^(d) maybe hydroxyl. The term “substituted amino” also refers to N-oxides of thegroups —NHR^(d), and NR^(d)R^(d) each as described above. N-oxides canbe prepared by treatment of the corresponding amino group with, forexample, hydrogen peroxide or m-chloroperoxybenzoic acid. The personskilled in the art is familiar with reaction conditions for carrying outthe N-oxidation.

“Aminocarbonyl” encompasses a group of the formula —(C═O)(optionallysubstituted amino) wherein substituted amino is as described herein.

“Acyl” refers to the groups (alkyl)-C(O)—; (cycloalkyl)-C(O)—;(aryl)-C(O)—; (heteroaryl)-C(O)—; and (heterocycloalkyl)-C(O)—, whereinthe group is attached to the parent structure through the carbonylfunctionality and wherein alkyl, cycloalkyl, aryl, heteroaryl, andheterocycloalkyl are as described herein. Acyl groups have the indicatednumber of carbon atoms, with the carbon of the keto group being includedin the numbered carbon atoms. For example a C₂ acyl group is an acetylgroup having the formula CH₃(C═O)—.

By “alkoxycarbonyl” is meant an ester group of the formula(alkoxy)(C═O)— attached through the carbonyl carbon wherein the alkoxygroup has the indicated number of carbon atoms. Thus aC₁-C₆alkoxycarbonyl group is an alkoxy group having from 1 to 6 carbonatoms attached through its oxygen to a carbonyl linker.

By “amino” is meant the group —NH₂.

The term “sulfinyl” includes the groups: —S(O)-(optionally substituted(C₁-C₆)alkyl), —S(O)-optionally substituted aryl), —S(O)-optionallysubstituted heteroaryl), —S(O)-(optionally substitutedheterocycloalkyl); and —S(O)-(optionally substituted amino).

The term “sulfonyl” includes the groups: —S(O₂)-(optionally substituted(C₁-C₆)alkyl), —S(O₂)-optionally substituted aryl), —S(O₂)-optionallysubstituted heteroaryl), —S(O₂)-(optionally substitutedheterocycloalkyl), —S(O₂)-(optionally substituted alkoxy),—S(O₂)-optionally substituted aryloxy), —S(O₂)-optionally substitutedheteroaryloxy), —S(O₂)-(optionally substituted heterocyclyloxy); and—S(O₂)-(optionally substituted amino).

The term “substituted acyl” refers to the groups (substitutedalkyl)-C(O)—; (substituted cycloalkyl)-C(O)—; (substituted aryl)-C(O)—;(substituted heteroaryl)-C(O)—; and (substitutedheterocycloalkyl)-C(O)—, wherein the group is attached to the parentstructure through the carbonyl functionality and wherein substitutedalkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are asdescribed herein.

The term “substituted alkoxy” refers to alkoxy wherein the alkylconstituent is substituted (i.e., —O-(substituted alkyl)) wherein“substituted alkyl” is as described herein.

The term “substituted alkoxycarbonyl” refers to the group (substitutedalkyl)-O—C(O)— wherein the group is attached to the parent structurethrough the carbonyl functionality and wherein substituted alkyl is asdescribed herein.

“Glycosides” refer to any of a number of sugar derivatives that containa non-sugar group bonded to an oxygen or nitrogen atom of a sugar andthat on hydrolysis yield that sugar. An example of a glycosyl group isglucosyl.

“Derivatives of ascorbic acid” or “ascorbic acid derivatives” refer toany of a number of derviatives that contain a non-sugar group bonded toan oxygen or nitrogen atom of ascorbic acid and that on hydrolysis yieldascorbic acid (i.e.,(R)-5-((S)-1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one).

Compounds described herein include, but are not limited to, theiroptical isomers, racemates, and other mixtures thereof. In thosesituations, the single enantiomers or diastereomers, i.e., opticallyactive forms, can be obtained by asymmetric synthesis or by resolutionof the racemates. Resolution of the racemates can be accomplished, forexample, by conventional methods such as crystallization in the presenceof a resolving agent, or chromatography, using, for example a chiralhigh-performance liquid chromatography (HPLC) column. In addition, suchcompounds include Z- and E-forms (or cis- and trans-forms) of compoundswith carbon-carbon double bonds. Where compounds described herein existin various tautomeric forms, the term “compound” is intended to includeall tautomeric forms of the compound. Such compounds also includecrystal forms including polymorphs and clathrates. Similarly, the term“salt” is intended to include all tautomeric forms and crystal forms ofthe compound.

Chemical entities include, but are not limited to compounds describedherein and all pharmaceutically acceptable forms thereof.Pharmaceutically acceptable forms of the compounds recited hereininclude pharmaceutically acceptable salts, prodrugs, and mixturesthereof. In some embodiments, the compounds described herein are in theform of pharmaceutically acceptable salts and prodrugs. Hence, the terms“chemical entity” and “chemical entities” also encompasspharmaceutically acceptable salts, prodrugs, and mixtures thereof.

“Pharmaceutically acceptable salts” include, but are not limited tosalts with inorganic acids, such as hydrochlorate, phosphate,diphosphate, hydrobromate, sulfate, sulfinate, nitrate, and like salts;as well as salts with an organic acid, such as malate, maleate,fumarate, tartrate, succinate, citrate, acetate, lactate,methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate,salicylate, stearate, and alkanoate such as acetate, HOOC—(CH₂)_(n)—COOHwhere n is 0-4, and like salts. Similarly, pharmaceutically acceptablecations include, but are not limited to sodium, potassium, calcium,aluminum, lithium, and ammonium.

In addition, if the compounds described herein are obtained as an acidaddition salt, the free base can be obtained by basifying a solution ofthe acid salt. Conversely, if the product is a free base, an additionsalt, particularly a pharmaceutically acceptable addition salt, may beproduced by dissolving the free base in a suitable organic solvent andtreating the solution with an acid, in accordance with conventionalprocedures for preparing acid addition salts from base compounds. Thoseskilled in the art will recognize various synthetic methodologies thatmay be used to prepare non-toxic pharmaceutically acceptable additionsalts.

As noted above, prodrugs also fall within the scope of chemical entitiesdescribed herein. In some embodiments, the “prodrugs” described hereininclude any compound that becomes a compound of Formula I whenadministered to a patient, e.g., upon metabolic processing of theprodrug. Examples of prodrugs include derivatives of functional groups,such as a carboxylic acid group, in the compounds of Formula I.Exemplary prodrugs of a carboxylic acid group include, but are notlimited to, carboxylic acid esters such as alkyl esters, hydroxyalkylesters, arylalkyl esters, and aryloxyalkyl esters. Other exemplaryprodrugs include lower alkyl esters such as ethyl ester, acyloxyalkylesters such as pivaloyloxymethyl (POM), glycosides, and ascorbic acidderivatives.

Other exemplary prodrugs include amides of carboxylic acids. Exemplaryamide prodrugs include metabolically labile amides that are formed, forexample, with an amine and a carboxylic acid. Exemplary amines includeNH₂, primary, and secondary amines such as NHR^(x), and NR^(x)R^(y),wherein R^(x) is hydrogen, (C₁-C₁₈-alkyl, (C₃-C₇)-cycloalkyl,(C₃-C₇)-cycloalkyl-(C₁-C₄)-alkyl-, (C₆-C₁₄)-aryl which is unsubstitutedor substituted by a residue (C₁-C₂)-alkyl, (C₁-C₂)-alkoxy, fluoro, orchloro; heteroaryl-, (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl- where aryl isunsubstituted or substituted by a residue (C₁-C₂)-alkyl, (C₁-C₂)-alkoxy,fluoro, or chloro; or heteroaryl-(C₁-C₄)-alkyl- and in which R^(y) hasthe meanings indicated for R^(x) with the exception of hydrogen orwherein R^(x) and R^(y), together with the nitrogen to which they arebound, form an optionally substituted 4- to 7-membered heterocycloalkylring which optionally includes one or two additional heteroatoms chosenfrom nitrogen, oxygen, and sulfur. A discussion of prodrugs is providedin T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol.14 of the A.C.S. Symposium Series, in Edward B. Roche, ed.,Bioreversible Carriers in Drug Design, American PharmaceuticalAssociation and Pergamon Press, 1987, and in Design of Prodrugs, ed. H.Bundgaard, Elsevier, 1985.

A “solvate” is formed by the interaction of a solvent and a compound.The term “compound” is intended to include solvates of compounds.Similarly, “salts” includes solvates of salts. Suitable solvates arepharmaceutically acceptable solvates, such as hydrates, includingmonohydrates and hemi-hydrates.

A “chelate” is formed by the coordination of a compound to a metal ionat two (or more) points. The term “compound” is intended to includechelates of compounds. Similarly, “salts” includes chelates of salts.

A “non-covalent complex” is formed by the interaction of a compound andanother molecule wherein a covalent bond is not formed between thecompound and the molecule. For example, complexation can occur throughvan der Waals interactions, hydrogen bonding, and electrostaticinteractions (also called ionic bonding). Such non-covalent complexesare included in the term “compound”.

The term “hydrogen bond” refers to a form of association between anelectronegative atom (also known as a hydrogen bond acceptor) and ahydrogen atom attached to a second, relatively electronegative atom(also known as a hydrogen bond donor). Suitable hydrogen bond donor andacceptors are well understood in medicinal chemistry (G. C. Pimentel andA. L. McClellan, The Hydrogen Bond, Freeman, San Francisco, 1960; R.Taylor and O. Kennard, “Hydrogen Bond Geometry in Organic Crystals”,Accounts of Chemical Research, 17, pp. 320-326 (1984)).

“Hydrogen bond acceptor” refers to a group comprising an oxygen ornitrogen, such as an oxygen or nitrogen that is sp²-hybridized, an etheroxygen, or the oxygen of a sulfoxide or N-oxide.

The term “hydrogen bond donor” refers to an oxygen, nitrogen, orheteroaromatic carbon that bears a hydrogen. group containing a ringnitrogen or a heteroaryl group containing a ring nitrogen.

As used herein the terms “group”, “radical” or “fragment” are synonymousand are intended to indicate functional groups or fragments of moleculesattachable to a bond or other fragments of molecules.

The term “active agent” is used to indicate a chemical entity which hasbiological activity. In some embodiments, an “active agent” is acompound having pharmaceutical utility. For example an active agent maybe an anti-neurodegenerative therapeutic.

The term “therapeutically effective amount” of a chemical entitydescribed herein means an amount effective, when administered to a humanor non-human patient, to provide a therapeutic benefit such asamelioration of symptoms, slowing of disease progression, or preventionof disease e.g., a therapeutically effective amount may be an amountsufficient to decrease the symptoms of a disease responsive toinhibition of KMO activity. In some embodiments, a therapeuticallyeffective amount is an amount sufficient to treat the symptoms ofneurodegenerative pathway or disease, such as Huntington's disease,Alzheimer's disease, Parkinson's disease, olivoponto cerebellar atrophy,non-Alzheimer's dementia, multi-infarctual dementia, cerebralamyotrophic lateral sclerosis, cerebral ischemia, cerebral hypoxia,spinal or head trauma, or epilepsy. In some embodiments atherapeutically effective amount is an amount sufficient to reduce thesigns or side effects of a neurodegenerative disease. In someembodiments, a therapeutically effective amount of a chemical entity isan amount sufficient to prevent a significant increase or significantlyreduce the level of neuronal cell death. In some embodiments atherapeutically effective amount is an amount sufficient to reduce thesigns or side effects of a neurodegenerative disease. In someembodiments, a therapeutically effective amount of a chemical entity isan amount sufficient to prevent a significant increase or significantlyreduce the level of QUIN associated with neuronal cell death. In someembodiments, a therapeutically effective amount of a chemical entity isan amount sufficient to effect an increase in the level of KYNAassociated with neuronal cell health. In some embodiments, atherapeutically effective amount of a chemical entity is an amountsufficient to increase the anticonvulsant and neuroprotective propertiesassociated with lowered levels of QUIN and increased levels of KYNA.

In methods described herein for treating a neurodegenerative disorder, atherapeutically effective amount may also be an amount sufficient, whenadministered to a patient, to detectably slow the progression of theneurodegenative disease, or prevent the patient to whom the chemicalentity is given from presenting symptoms of the neurodegenative disease.In some methods described herein for treating a neurodegenative disease,a therapeutically effective amount may also be an amount sufficient toproduce a detectable decrease in the level of neuronal cell death. Forexample, in some embodiments a therapeutically effective amount is anamount of a chemical entity described herein sufficient to significantlydecrease the level of neuronal death by effecting a detectable decreasein the amount of QUIN, and an increase in the amount of KYNA.

The term “inhibition” indicates a significant decrease in the baselineactivity of a biological activity or process. “Inhibition of KMOactivity” refers to a decrease in KMO activity as a direct or indirectresponse to the presence of at least one chemical entity describedherein, relative to the activity of KMO in the absence of at least onechemical entity. The decrease in activity may be due to the directinteraction of the compound with KMO, or due to the interaction of thechemical entity(ies) described herein with one or more other factorsthat in turn affect KMO activity. For example, the presence of thechemical entity(ies) may decrease KMO activity by directly binding tothe KMO, by causing (directly or indirectly) another factor to decreaseKMO activity, or by (directly or indirectly) decreasing the amount ofKMO present in the cell or organism.

“Inhibition of KMO activity” refers to a decrease in KMO activity as adirect or indirect response to the presence of at least one chemicalentity described herein, relative to the activity of KMO in the absenceof the at least one chemical entity. The decrease in activity may be dueto the direct interaction of the compound with KMO or with one or moreother factors that in turn affect KMO activity.

Inhibition of KMO activity also refers to an observable inhibition of3-HK and QUIN production in a standard assay such as the assay describedbelow. The inhibition of KMO activity also refers to an observableincrease in the production of KYNA. In some embodiments, the chemicalentity described herein has an IC₅₀ value less than or equal to 1micromolar. In some embodiments, the chemical entity has an IC₅₀ valueless than or equal to less than 100 micromolar. In some embodiments, thechemical entity has an IC₅₀ value less than or equal to 10 nanomolar.

“KMO activity” also includes activation, redistribution, reorganization,or capping of one or more various KMO membrane receptors, or receptorsites can undergo redistribution and capping that can initiate signaltransduction. KMO activity also includes the synthesis or production ofQUIN and 3-HK.

A “disease responsive to inhibition of KMO activity” is a disease inwhich inhibiting KMO provides a therapeutic benefit such as anamelioration of symptoms, decrease in disease progression, prevention ordelay of disease onset, or inhibition of aberrant activity and/or deathof certain cell-types (neuronal cells).

“Treatment” or “treating” means any treatment of a disease in a patient,including:

-   -   a) preventing the disease, that is, causing the clinical        symptoms of the disease not to develop;    -   b) inhibiting the disease;    -   c) slowing or arresting the development of clinical symptoms;        and/or    -   d) relieving the disease, that is, causing the regression of        clinical symptoms.

“Subject” or “patient” refers to an animal, such as a mammal, that hasbeen or will be the object of treatment, observation or experiment. Themethods described herein may be useful in both human therapy andveterinary applications. In some embodiments, the subject is a mammal;and in some embodiments the subject is human.

Provided is at least one chemical entity chosen from compounds offormula I

and pharmaceutically acceptable salts and prodrugs thereof wherein:

-   X and Y are independently chosen from CH and N provided that at    least one of X and Y is N;-   R₁ is chosen from aryl and heteroaryl, each of which is substituted    with one, two, or three groups chosen from halo, optionally    substituted lower alkyl, lower alkoxy, optionally substituted amino,    optionally substituted heterocycloalkyl, optionally substituted    heteroaryl, and hydroxy;-   L is chosen from —C(O)O—, —C(O)N(R₃)—, —N(R₃)C(O)—, —N(R₃)S(O)₂—,    and —S(O)₂N(R₃)—;-   R₂ is chosen from hydrogen, optionally substituted lower alkyl,    optionally substituted aryl, optionally substituted heteroaryl,    optionally substituted cycloalkyl, and optionally substituted    heterocycloalkyl, provided that when L is —N(R₃)S(O)₂—, R₂ is not    hydrogen;-   R₃ is chosen from hydrogen and lower alkyl; or-   R₂ and R₃, taken together with any intervening atoms, forms an    optionally substituted heterocycloalkyl ring;-   R₄ is chosen from hydrogen and optionally substituted lower alkyl;-   R₅ is chosen from hydrogen and fluoro,-   provided that the compound of Formula I is not    -   N-(1-hydroxy-3-(1H-indol-3-yl)propan-2-yl)-6-(4-methoxyphenyl)pyrimidine-4-carboxamide,-   3-chloro-2-methyl-N-(6-phenylpyrimidin-4-yl)benzenesulfonamide;-   4-methoxy-N-(6-phenylpyrimidin-4-yl)benzamide;-   N-(6-phenylpyrimidin-4-yl)benzamide;-   6-phenylpyrimidine-4-carboxylic acid;-   methyl 6-phenylpyrimidine-4-carboxylate;-   ethyl 6-phenylpyrimidine-4-carboxylate;-   6-phenylpyrimidine-4-carboxamide;-   N-methyl-6-phenylpyrimidine-4-carboxamide; or-   N,N-dimethyl-6-phenylpyrimidine-4-carboxamide.

In some embodiments, the compound of Formula I is chosen from compoundsof Formula II

wherein:

-   R₁ is chosen from aryl and heteroaryl, each of which is substituted    with one, two, or three groups chosen from halo, lower alkyl, lower    alkoxy, optionally substituted amino, optionally substituted    heterocycloalkyl, optionally substituted heteroaryl, and hydroxy;-   L is chosen from —C(O)O—, —C(O)N(R₃)—, —N(R₃)C(O)—, —N(R₃)S(O)₂—,    and —S(O)₂N(R₃)—;-   R₂ is chosen from hydrogen, optionally substituted lower alkyl,    optionally substituted aryl, optionally substituted heteroaryl,    optionally substituted cycloalkyl, and optionally substituted    heterocycloalkyl, provided that when L is —N(R₃)S(O)₂—, R₂ is not    hydrogen;-   R₃ is chosen from hydrogen and lower alkyl; and-   R₄ is chosen from hydrogen and optionally substituted lower alkyl;    provided that the compound of Formula II is not-   N-(1-hydroxy-3-(1H-indol-3-yl)propan-2-yl)-6-(4-methoxyphenyl)pyrimidine-4-carboxamide,-   3-chloro-2-methyl-N-(6-phenylpyrimidin-4-yl)benzenesulfonamide;-   4-methoxy-N-(6-phenylpyrimidin-4-yl)benzamide;-   N-(6-phenylpyrimidin-4-yl)benzamide;-   6-phenylpyrimidine-4-carboxylic acid;-   methyl 6-phenylpyrimidine-4-carboxylate;-   ethyl 6-phenylpyrimidine-4-carboxylate;-   6-phenylpyrimidine-4-carboxamide;-   N-methyl-6-phenylpyrimidine-4-carboxamide; or-   N,N-dimethyl-6-phenylpyrimidine-4-carboxamide.

In some embodiments, R₁ is phenyl optionally substituted with one, two,or three groups chosen from halo, lower alkyl, lower alkoxy, optionallysubstituted amino, optionally substituted heterocycloalkyl, optionallysubstituted heteroaryl, and hydroxy. In some embodiments, R₁ is phenyloptionally substituted with one, two, or three groups chosen from halo,optionally substituted lower alkyl, optionally substituted lower alkoxy,and hydroxy. In some embodiments, R₁ is phenyl optionally substitutedwith one, two, or three groups chosen from halo, lower alkyl,trifluoromethyl, lower alkoxy, and hydroxy. In some embodiments, R₁ isphenyl optionally substituted with one, two, or three groups chosen fromhalo, lower alkyl, and trifluoromethyl. In some embodiments, R₁ ischosen from phenyl, 2,4-difluorophenyl, 3-chloro-2-fluorophenyl,3-chloro-4-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl,3-fluoro-5-trifluoromethylphenyl, 3-trifluoromethylphenyl,4-fluoro-3-trifluoromethylphenyl, 2-trifluoromethylphenyl,3,4-dichlorophenyl, 3-chlorophenyl, 4-chlorophenyl, and3,5-dichlorophenyl. In some embodiments, R₁ is chosen from2-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chlorophenyl,4-chlorophenyl, and 3,5-dichlorophenyl.

In some embodiments, R₁ is pyridin-3-yl optionally substituted with one,two, or three groups chosen from halo, lower alkyl, lower alkoxy,optionally substituted amino, optionally substituted heterocycloalkyl,optionally substituted heteroaryl, and hydroxy. In some embodiments, R₁is pyridin-3-yl optionally substituted with one, two, or three groupschosen from halo, optionally substituted lower alkyl, optionallysubstituted lower alkoxy, and hydroxy. In some embodiments, R₁ ispyridin-3-yl optionally substituted with one, two, or three groupschosen from halo, lower alkyl, trifluoromethyl, lower alkoxy, andhydroxy. In some embodiments, R₁ is pyridin-3-yl optionally substitutedwith one, two, or three groups chosen from halo, lower alkyl, andtrifluoromethyl. In some embodiments, R₁ is chosen from pyridin-3-yl,5-fluoropyridin-3-yl, and 5-chloropyridin-3-yl.

In some embodiments, L is chosen from —C(O)O—, —C(O)N(R₃)—, and—N(R₃)S(O)₂—. In some embodiments, L is —C(O)N(R₃)—. In someembodiments, L is —N(R₃)S(O)₂—. In some embodiments, L is —C(O)O—.

In some embodiments, R₃ is hydrogen. In some embodiments, R₃ is loweralkyl. In some embodiments, R₃ is methyl.

In some embodiments, R₄ is chosen from hydrogen and lower alkyl. In someembodiments, R₄ is hydrogen. In some embodiments, R₄ is lower alkyl. Insome embodiments, R₄ is methyl.

In some embodiments, R₂ is chosen from hydrogen, lower alkyl, optionallysubstituted heteroaryl, and optionally substituted phenyl. In someembodiments, R₂ is chosen from hydrogen, lower alkyl, optionallysubstituted pyridinyl, and optionally substituted phenyl. In someembodiments, R₂ is chosen from hydrogen, lower alkyl, pyridinyl, andphenyl, wherein the pyridinyl and phenyl groups are each optionallysubstituted with one or two groups chosen from halo, hydroxy, loweralkyl, and lower alkoxy. In some embodiments, R₂ is chosen fromhydrogen, lower alkyl, pyridinyl, and phenyl, wherein the phenyl groupis optionally substituted with one or two groups chosen from halo,hydroxy, lower alkyl, and lower alkoxy.

In some embodiments, R₂ and R₃, taken together with any interveningatoms, forms an optionally substituted heterocycloalkyl ring. In someembodiments, R₂ and R₃, taken together with any intervening atoms, formsan optionally substituted heterocycloalkyl ring chosen frommorpholin-4-yl, 3,4-dihydroquinolin-1(2H)-yl, indolin-1-yl,3-oxopiperazin-1-yl, piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl,azetidin-1-yl, and isoindolin-2-yl, each of which is optionallysubstituted. In some embodiments, R₂ and R₃, taken together with anyintervening atoms, forms an optionally substituted heterocycloalkyl ringchosen from morpholin-4-yl, 3,4-dihydroquinolin-1(2H)-yl, indolin-1-yl,3-oxopiperazin-1-yl, piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl,azetidin-1-yl, and isoindolin-2-yl, each of which is optionallysubstituted with one or two groups chosen from halo, hydroxy, loweralkyl, lower alkoxy, —C(O)(lower alkyl), —C(O)NH₂, —C(O)N(H)(loweralkyl), and —C(O)(lower alkyl)(lower alkyl).

In some embodiments, R₅ is hydrogen. In some embodiments, R₅ is fluoro.

In some embodiments, X is N and Y is CH.

In some embodiments, X is CH and Y is N.

In some embodiments, X is N and Y is N.

Also provided is at least one chemical entity chosen from

-   6-(2-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;-   N-[6-(2-Trifluoromethyl-phenyl)-pyrimidin-4-yl]-methanesulfonamide;-   3,4-Dimethoxy-N-[6-(2-trifluoromethyl-phenyl)-pyrimidin-4-yl]-benzenesulfonamide;-   N-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-methanesulfonamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   N-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulfonamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-3-ylamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   N-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-nicotinamide;-   6-(3,4-Dichloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid methyl    ester;-   6-(3,4-Dichloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (2,6-dimethyl-pyridin-3-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    pyrimidin-5-ylamide;-   6-(4-Morpholin-4-yl-phenyl)-pyrimidine-4-carboxylic acid methyl    ester;-   6-(4-Fluoro-3-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid    methyl ester;-   6-(3-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid methyl    ester;-   6-(4-Fluoro-3-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid    pyridin-2-ylamide;-   6-(4-Fluoro-3-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid ethylamide;-   6-(5-Fluoro-pyridin-3-yl)-pyrimidine-4-carboxylic acid;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid amide;-   6-(3-Fluoro-5-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid    methyl ester;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid methylamide;-   6-(5-Fluoro-pyridin-3-yl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(3-Fluoro-5-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;-   6-(5-Chloro-pyridin-3-yl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(5-Chloro-pyridin-3-yl)-pyrimidine-4-carboxylic acid;-   6-(2-Fluoro-5-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid    methyl ester;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid isopropylamide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-morpholin-4-yl-methanone;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid propylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid phenylamide;-   6-Phenyl-pyrimidine-4-carboxylic acid;-   6-(2-Fluoro-5-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid o-tolylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid p-tolylamide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(3,4-dihydro-2H-quinolin-1-yl)-methanone;-   6-Phenyl-pyrimidine-4-carboxylic acid methyl ester;-   6-(2,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(2,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (6-methoxy-pyridin-3-yl)-amide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(2,3-dihydro-indol-1-yl)-methanone;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid m-tolylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    methyl-pyridin-3-yl-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (5-methoxy-pyridin-3-yl)-amide;-   6-(3-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid methyl    ester;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid dimethylamide;-   6-(3-Chloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid methyl    ester;-   4-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-piperazin-2-one;-   6-Phenyl-pyrimidine-4-carboxylic acid pyridin-3-ylamide;-   6-(3-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenylamino)-pyrimidine-4-carboxylic acid methyl    ester;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (4-methoxy-pyridin-3-yl)-amide;-   6-(3-Chloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid;-   6-(3-Chloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (2-hydroxy-ethyl)-amide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(4-hydroxy-piperidin-1-yl)-methanone;-   6-(3-Methoxy-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3-Methoxy-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid benzylamide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(4-methyl-piperazin-1-yl)-methanone;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-pyrrolidin-1-yl-methanone;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    ((S)-2-hydroxy-propyl)-amide;-   6-m-Tolyl-pyrimidine-4-carboxylic acid methyl ester;-   1-{4-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-piperazin-1-yl}-ethanone;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    ((R)-2-hydroxy-propyl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (2-methoxy-phenyl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (4-methoxy-phenyl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (3-methoxy-phenyl)-amide; Sodium;    6-(3-chloro-phenyl)-pyrimidine-4-sulfonate;-   6-m-Tolyl-pyrimidine-4-carboxylic acid;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    methyl-phenyl-amide;-   [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(2,3-dihydro-indol-1-yl)-methanone;-   N-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-methanesulfonamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-2-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-4-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (pyridin-4-ylmethyl)-amide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(4-methyl-piperidin-1-yl)-methanone;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-((R)-3-hydroxy-pyrrolidin-1-yl)-methanone;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    [1,3,4]thiadiazol-2-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid isoxazol-3-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    ((R)-1-phenyl-ethyl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    ((S)-1-phenyl-ethyl)-amide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-((S)-3-hydroxy-pyrrolidin-1-yl)-methanone;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylicacid[4-(4-methyl-piperazin-1-yl)-phenyl]-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (6-trifluoromethyl-pyridin-3-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (pyridin-3-ylmethyl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    pyridazin-3-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid pyrazin-2-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (4-morpholin-4-yl-phenyl)-amide;-   (S)-1-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-pyrrolidine-2-carboxylic    acid amide;-   (R)-1-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-pyrrolidine-2-carboxylic    acid amide;-   Azetidin-1-yl-[6-(3-chloro-phenyl)-pyrimidin-4-yl]-methanone;-   6-(4-Methoxy-phenyl)-pyrimidine-4-carboxylic acid;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(1,3-dihydro-isoindol-2-yl)-methanone;-   [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(3,4-dihydro-2H-quinolin-1-yl)-methanone;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid phenylamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid p-tolylamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (5-methoxy-pyridin-3-yl)-amide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    pyrimidin-5-ylamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (6-methyl-pyridin-3-yl)-amide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (2-methyl-pyridin-3-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    pyrimidin-2-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    methyl-p-tolyl-amide;-   6-(3-Fluoro-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (6-methyl-pyridin-3-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (2-methyl-pyridin-3-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (4-fluoro-phenyl)-amide;-   6-(3-Fluoro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid phenylamide;-   [6-(3,5-Dichloro-phenyl)-pyrimidin-4-yl]-(2,3-dihydro-indol-1-yl)-methanone;-   6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid p-tolylamide;-   6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (5-methoxy-pyridin-3-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (1-methyl-1H-pyrazol-3-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (1-methyl-1H-pyrazol-4-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (4-methoxy-phenyl)-methyl-amide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(2-methyl-2,3-dihydro-indol-1-yl)-methanone;-   6-(3-Fluoro-phenyl)-pyrimidine-4-carboxylic acid pyridin-3-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (2,2-difluoro-benzo[1,3]dioxol-5-yl)-amide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(5-fluoro-2,3-dihydro-indol-1-yl)-methanone;-   (5-Chloro-2,3-dihydro-indol-1-yl)-[6-(3-chloro-phenyl)-pyrimidin-4-yl]-methanone;-   6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    pyrimidin-5-ylamide;-   6-(3-Chloro-4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid    methyl ester;-   6-(3-Chloro-4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3-Chloro-4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(2,3-dihydro-pyrrolo[3,2-c]pyridin-1-yl)-methanone;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (2,2-difluoro-benzo[1,3]dioxol-5-yl)-methyl-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid thiazol-2-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (3-methyl-isoxazol-5-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (5-methyl-[1,3,4]oxadiazol-2-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid oxazol-2-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (3-methyl-[1,2,4]thiadiazol-5-yl)-amide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (4H-[1,2,4]triazol-3-yl)-amide;-   6-(3,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(5-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid methyl    ester;-   6-(3,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid    pyrimidin-5-ylamide;-   6-(5-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid;-   [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(1′,2′-dihydro-spiro[cyclopropane-1,3′-[3H]indol]-1′)-methanone;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (2,6-dimethyl-pyridin-3-yl)-amide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (3-methyl-isoxazol-5-yl)-amide;-   6-(3-Chloro-4-fluoro-phenyl)-pyrimidine-4-carboxylic acid methyl    ester;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (5-methyl-[1,3,4]oxadiazol-2-yl)-amide;-   6-(3-Chloro-4-methoxy-phenyl)-pyrimidine-4-carboxylic acid methyl    ester;-   6-(3-Chloro-4-methoxy-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (pyridin-4-ylmethyl)-amide;-   6-(3-Chloro-4-fluoro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    [1,3,4]thiadiazol-2-ylamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (2-amino-ethyl)-amide;    -   (5-Chloro-2,3-dihydro-indol-1-yl)-[6-(3,4-dichloro-phenyl)-pyrimidin-4-yl]-methanone;-   [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(5-fluoro-2,3-dihydro-indol-1-yl)-methanone;-   [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(5-morpholin-4-yl-2,3-dihydro-indol-1-yl)-methanone;-   6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    pyridin-4-ylamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    pyridin-2-ylamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (1-methyl-1H-pyrazol-4-yl)-amide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    isoxazol-3-ylamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    thiazol-2-ylamide;-   [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(1,3-dihydro-isoindol-2-yl)-methanone;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (4H-[1,2,4]triazol-3-yl)-amide;-   4-(3,4-Dichloro-phenyl)-6-(5-fluoro-pyridin-2-yl)-pyrimidine;-   6-(3,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid    pyrimidin-5-ylamide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (2-methyl-pyrimidin-5-yl)-amide;-   6-(3-Chloro-4-methyl-phenyl)-pyrimidine-4-carboxylic acid methyl    ester;-   6-(3-Chloro-4-methyl-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3-Chloro-4-fluoro-phenyl)-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3-Chloro-4-fluoro-phenyl)-pyrimidine-4-carboxylic acid    (2,6-dimethyl-pyridin-3-yl)-amide;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (2-acetylamino-ethyl)-amide;-   [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(3,3-dimethyl-2,3-dihydro-indol-1-yl)-methanone;-   [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(4-hydroxy-piperidin-1-yl)-methanone;-   [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-morpholin-4-yl-methanone;-   6-(3-Chloro-4-fluoro-phenyl)-pyrimidine-4-carboxylic acid    pyrimidin-5-ylamide;-   6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acid methyl    ester;-   6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acid    (2,6-dimethyl-pyridin-3-yl)-amide;-   6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acid    pyrimidin-5-ylamide;-   2-(3-Chloro-phenyl)-isonicotinic acid methyl ester;-   4-(3-Chloro-phenyl)-pyridine-2-carboxylic acid;-   4-(3-Chloro-phenyl)-pyridine-2-carboxylic acid methyl ester;-   4-(3-Chloro-phenyl)-pyridine-2-carboxylic acid pyridin-3-ylamide;-   4-(3-Chloro-phenyl)-pyridine-2-carboxylic acid phenylamide;-   [4-(3-Chloro-phenyl)-pyridin-2-yl]-(2,3-dihydro-indol-1-yl)-methanone;-   4-(3-Chloro-phenyl)-pyridine-2-carboxylic acid p-tolylamide;-   4-(3-Chloro-phenyl)-pyridine-2-carboxylic acid    (5-methoxy-pyridin-3-yl)-amide;-   4-(3,5-Dichloro-phenyl)-pyridine-2-carboxylic acid phenylamide;-   4-(3,5-Dichloro-phenyl)-pyridine-2-carboxylic acid p-tolylamide;-   4-(3,5-Dichloro-phenyl)-pyridine-2-carboxylic acid    pyridin-3-ylamide;-   4-(3,5-Dichloro-phenyl)-pyridine-2-carboxylic acid    (5-methoxy-pyridin-3-yl)-amide;-   [4-(3,5-Dichloro-phenyl)-pyridin-2-yl]-(2,3-dihydro-indol-1-yl)-methanone;-   4-(3-Chloro-phenyl)-pyridine-2-carboxylic acid pyrimidin-5-ylamide;-   4-(3,4-Dichloro-phenyl)-pyridine-2-carboxylic acid phenylamide;-   4-(3,4-Dichloro-phenyl)-pyridine-2-carboxylic acid p-tolylamide;-   4-(3,4-Dichloro-phenyl)-pyridine-2-carboxylic acid    pyridin-3-ylamide;-   [4-(3,4-Dichloro-phenyl)-pyridin-2-yl]-(2,3-dihydro-indol-1-yl)-methanone;-   4-(3,4-Dichloro-phenyl)-pyridine-2-carboxylic acid    (5-methoxy-pyridin-3-yl)-amide;-   4-(3,4-Dichloro-phenyl)-pyridine-2-carboxylic acid    pyrimidin-5-ylamide;-   4-(3,5-Dichloro-phenyl)-pyridine-2-carboxylic acid    pyrimidin-5-ylamide; and-   5-Morpholin-4-yl-pyridine-2-carboxylic acid tert-butyl ester,    and pharmaceutically acceptable salts and prodrugs thereof.

Also provided is at least one chemical entity chosen from

-   6-(3-chloro-phenyl)-pyrimidine-4-carboxylic acid sodium salt;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid cyclohexyl ammonium    salt;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-3-ylamide    hydrochloride salt;-   6-(3,4-dichloro-phenyl)-pyrimidine-4-carboxylic acid sodium salt;-   6-Pyridin-3-yl-pyrimidine-4-carboxylic acid methyl ester    trifluoroacetic acid salt;-   6-Morpholin-4-yl-pyrimidine-4-carboxylic acid hydrochloride salt;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (6-methyl-pyridin-3-yl)-amide hydrochloride salt;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    (2,6-dimethyl-pyridin-3-yl)-amide hydrochloride salt;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-sulfonate sodium salt;-   2-(3-Chloro-phenyl)-isonicotinic acid hydrochloride salt;-   4-(3,5-Dichloro-phenyl)-pyridine-2-carboxylic acid hydrocloride    salt; and-   4-(3,4-Dichloro-phenyl)-pyridine-2-carboxylic acid hydrochloride    salt.

Also provided is at least one chemical entity chosen from6-(2-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid methyl ester;

-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid methyl ester;-   6-(3,4-Dichloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid methyl    ester;-   6-(2-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid;-   6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-3-ylamide;-   6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid    (2,6-dimethyl-pyridin-3-yl)-amide;-   6-(3,4-Dichloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid    pyridin-3-ylamide;-   N-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-nicotinamide;-   N-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulfonamide;-   3,4-Dimethoxy-N-[6-(2-trifluoromethyl-phenyl)-pyrimidin-4-yl]-benzenesulfonamide;-   N-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-methanesulfonamide; and-   N-[6-(2-Trifluoromethyl-phenyl)-pyrimidin-4-yl]-methanesulfonamide;

and pharmaceutically acceptable salts and prodrugs thereof.

Also provided is a method of treating a condition or disorder mediatedby Kynurenine 3-mono-oxygenase activity in a subject in need of such atreatment which method comprises administering to the subject atherapeutically effective amount of at least one chemical entitydescribed herein.

Methods for obtaining the chemical entities described herein will beapparent to those of ordinary skill in the art, suitable proceduresbeing described, for example, in the reaction schemes and examplesbelow, and in the references cited herein.

Referring to Reaction Scheme 1, Step 1, a compound of formula 101, acompound of formula R₁B(OH)₂ and Pd(PPh₃)₄ are suspended in a suitablesolvent such as dioxane in a pressure tube. A base such as aqueouspotassium carbonate, for example, 2 M K₂CO₃ solution, is added and thereaction mixture is heated at about 90° C. under an inert atmosphere.The reaction mixture is cooled to room temperature and the product, acompound of formula 103, is isolated and optionally purified.

Referring to Reaction Scheme 1, Step 2, a compound of formula 103,PdCl₂(dppf). DCM and triethylamine are suspended in a suitable solvent,such as degassed MeOH in a vessel fitted with a magnetic stirrer bar.The vessel is pressurised to about 5 bar of CO and heated at about 50°C. with stirring for about 5 hours. The reaction vessel is allowed tocool and the product, a compound of formula 105, is isolated andoptionaly purified.

Referring to Reaction Scheme 1, Step 3, a compound of formula 105 issuspended in an appropriate solvent such as methanol. Aqueous base, suchas aqueous sodium hydroxide, for example, 1M NaOH solution, is added andthe reaction mixture is stirred at room temperature for about 4 hours.The product, a compound of formula 107, is isolated and optionallypurified.

Referring to Reaction Scheme 1, Step 4, to a solution of a compound offormula 107 in a suitable solvent such as DMF are added EDC.HCl andHOBt. The reaction mixture is stirred at ambient temperature for about30 minutes after which time an amine of formula R₂NH₂ is added. Theproduct, a compound of formula 109, is isolated and optionally purified.

Referring to Reaction Scheme 2, Step 1, a compound of formula 201 issuspended in ammonium hydroxide before irradiation at about 100° C. in amicrowave for about 1 hour with stirring. The product, a compound offormula 203, is isolated and optionally purified.

Referring to Reaction Scheme 2, Step 2, a compound of formula 203 issuspended in a suitable solvent such as dioxane. An excess of sodiumhydride (such as about 3 to 10 equivalents) is added and the suspensionis stirred for about 30 minutes at room temperature. An excess (such asabout 1.1 equivalents) of a compound of formula R₂S(O)₂Cl is added andthe reaction mixture stirred at room temperature. The product, acompound of formula 205, is isolated and optionally purified.

Referring to Reaction Scheme 2, Step 3, a compound of formula 203 issuspended in an inert solvent such as dioxane. A base such as sodiumhydride is added and the suspension is stirred for about 30 minutes atroom temperature. An excess (such as about 1.1 equivalents) of thecorresponding acid chloride of formula Cl—C(O)—R₃ is added and thereaction mixture is stirred at room temperature for about 3 days.Optionally further base may be added. The product, a compound of formula207, is isolated and optionally purified.

Provided is a method of inhibiting the catalytic activity of KMO,comprising contacting said KMO with an effective amount of at least onechemical entity described herein.

Also provided is a method of treating a condition or disorder mediatedby KMO activity in a subject in need of such a treatment, comprisingadministering to the subejct a therapeutically effective amount of atleast one chemical entity described herein.

Also provided is a method of treating a neurodegenerative pathologymediated by KMO activity in a subject in need of such a treatment,comprising administering to the subject a therapeutically effectiveamount of at least one chemical entity described herein. Also providedis a method for treating disorders mediated by (or at least in part by)the presence of KYNA and/or QUIN. Such diseases include, for example,Huntington's disease and other polyglutamine disorders such asspinocerebellar ataxias, Alzheimer's disease, Parkinson's disease,high-pressure neurological syndrome, dystonia, olivopontocerebellaratrophy, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy,consequences of stroke, cerebral ischemia, hypoxia, multi-infarctdementia, consequences of cerebral trauma or damage, damage to thespinal cord, AIDS-dementia complex, viral or bacterial meningitis,general central nervous system (CNS) infections such as viral, bacterialor parasites, for example, poliomyelitis, Lyme disease (Borreliaburgdorferi infection) and malaria, cancers with cerebral localization,Tourette's syndrome, hepatic encephalopathy, systemic lupus, analgesiaand opiate withdrawal symptoms, feeding behavior, schizophrenia, chronicanxiety, depressive disorders, disorders of the developing or agedbrain, diabetes, and complications thereof, comprising administering tothe subject an effective amount of at least one chemical entitydescribed herein.

Also provided are methods of treatment in which at least one chemicalentity described herein is the only active agent given to the subjectand also includes methods of treatment in which at least one chemicalentity described herein is given to the subject in combination with oneor more additional active agents.

In general, the chemical entities described herein will be administeredin a therapeutically effective amount by any of the accepted modes ofadministration for agents that serve similar utilities. The actualamount of the compound, i.e., the active ingredient, will depend uponnumerous factors such as the severity of the disease to be treated, theage and relative health of the subject, the potency of the compoundused, the route and form of administration, and other factors well knowto the skilled artisan. The drug can be administered at least once aday, such as once or twice a day.

In some embodiments, the chemical entities described herein areadministered as a pharmaceutical composition. Accordingly, provided arepharmaceutical compositions comprising at least one chemical entitydescribed herein, together with at least one pharmaceutically acceptablevehicle chosen from carriers, adjuvants, and excipients.

Pharmaceutically acceptable vehicles must be of sufficiently high purityand sufficiently low toxicity to render them suitable for administrationto the animal being treated. The vehicle can be inert or it can possesspharmaceutical benefits. The amount of vehicle employed in conjunctionwith the chemical entity is sufficient to provide a practical quantityof material for administration per unit dose of the chemical entity.

Exemplary pharmaceutically acceptable carriers or components thereof aresugars, such as lactose, glucose and sucrose; starches, such as cornstarch and potato starch; cellulose and its derivatives, such as sodiumcarboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powderedtragacanth; malt; gelatin; talc; solid lubricants, such as stearic acidand magnesium stearate; calcium sulfate; synthetic oils; vegetable oils,such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil;polyols such as propylene glycol, glycerine, sorbitol, mannitol, andpolyethylene glycol; alginic acid; phosphate buffer solutions;emulsifiers, such as the TWEENS; wetting agents, such sodium laurylsulfate; coloring agents; flavoring agents; tableting agents;stabilizers; antioxidants; preservatives; pyrogen-free water; isotonicsaline; and phosphate buffer solutions.

Optional active agents may be included in a pharmaceutical composition,which do not substantially interfere with the activity of the chemicalentity described herein.

Effective concentrations of at least one chemical entity describedherein are mixed with a suitable pharmaceutically acceptable vehicle. Ininstances in which the chemical entity exhibits insufficient solubility,methods for solubilizing compounds may be used. Such methods are knownto those of skill in this art, and include, but are not limited to,using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants,such as TWEEN, or dissolution in aqueous sodium bicarbonate.

Upon mixing or addition of a chemical entity described herein, theresulting mixture may be a solution, suspension, emulsion or the like.The form of the resulting mixture depends upon a number of factors,including the intended mode of administration and the solubility of thechemical entity in the chosen vehicle. The effective concentrationsufficient for ameliorating the symptoms of the disease treated may beempirically determined.

Chemical entities described herein may be administered orally,topically, parenterally, intravenously, by intramuscular injection, byinhalation or spray, sublingually, transdermally, via buccaladministration, rectally, as an ophthalmic solution, or by other means,in dosage unit formulations.

Pharmaceutical compositions may be formulated for oral use, such as forexample, tablets, troches, lozenges, aqueous or oily suspensions,dispersible powders or granules, emulsions, hard or soft capsules, orsyrups or elixirs. Pharmaceutical compositions intended for oral use maybe prepared according to any method known to the art for the manufactureof pharmaceutical compositions and such compositions may contain one ormore agents, such as sweetening agents, flavoring agents, coloringagents and preserving agents, in order to provide pharmaceuticallyelegant and palatable preparations. In some embodiments, oralpharmaceutical compositions contain from 0.1 to 99% of at least onechemical entity described herein. In some embodiments, oralpharmaceutical compositions contain at least 5% (weight %) of at leastone chemical entity described herein. Some embodiments contain from 25%to 50% or from 5% to 75% of at least one chemical entity describedherein.

Orally administered pharmaceutical compositions also include liquidsolutions, emulsions, suspensions, powders, granules, elixirs,tinctures, syrups, and the like. The pharmaceutically acceptablecarriers suitable for preparation of such compositions are well known inthe art. Oral pharmaceutical compositions may contain preservatives,flavoring agents, sweetening agents, such as sucrose or saccharin,taste-masking agents, and coloring agents.

Typical components of carriers for syrups, elixirs, emulsions andsuspensions include ethanol, glycerol, propylene glycol, polyethyleneglycol, liquid sucrose, sorbitol and water. Syrups and elixirs may beformulated with sweetening agents, for example glycerol, propyleneglycol, sorbitol or sucrose. Such pharmaceutical compositions may alsocontain a demulcent.

Chemical entities described herein can be incorporated into oral liquidpreparations such as aqueous or oily suspensions, solutions, emulsions,syrups, or elixirs, for example. Moreover, pharmaceutical compositionscontaining these chemical entities can be presented as a dry product forconstitution with water or other suitable vehicle before use. Suchliquid preparations can contain conventional additives, such assuspending agents (e.g., sorbitol syrup, methyl cellulose,glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethylcellulose, aluminum stearate gel, and hydrogenated edible fats),emulsifying agents (e.g., lecithin, sorbitan monsoleate, or acacia),non-aqueous vehicles, which can include edible oils (e.g., almond oil,fractionated coconut oil, silyl esters, propylene glycol and ethylalcohol), and preservatives (e.g., methyl or propyl p-hydroxybenzoateand sorbic acid).

For a suspension, typical suspending agents include methylcellulose,sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth and sodiumalginate; typical wetting agents include lecithin and polysorbate 80;and typical preservatives include methyl paraben and sodium benzoate.

Aqueous suspensions contain the active material(s) in admixture withexcipients suitable for the manufacture of aqueous suspensions. Suchexcipients are suspending agents, for example sodiumcarboxymethylcellulose, methylcellulose, hydropropylmethylcellulose,sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia;dispersing or wetting agents; may be a naturally-occurring phosphatide,for example, lecithin, or condensation products of an alkylene oxidewith fatty acids, for example polyoxyethylene stearate, or condensationproducts of ethylene oxide with long chain aliphatic alcohols, forexample heptadecaethyleneoxycetanol, or condensation products ofethylene oxide with partial esters derived from fatty acids and ahexitol such as polyoxyethylene sorbitol substitute, or condensationproducts of ethylene oxide with partial esters derived from fatty acidsand hexitol anhydrides, for example polyethylene sorbitan substitute.The aqueous suspensions may also contain one or more preservatives, forexample ethyl, or n-propyl p-hydroxybenzoate.

Oily suspensions may be formulated by suspending the active ingredientsin a vegetable oil, for example peanut oil, olive oil, sesame oil orcoconut oil, or in a mineral oil such as liquid paraffin. The oilysuspensions may contain a thickening agent, for example beeswax, hardparaffin or cetyl alcohol. Sweetening agents such as those set forthabove, and flavoring agents may be added to provide palatable oralpreparations. These pharmaceutical compositions may be preserved by theaddition of an anti-oxidant such as ascorbic acid.

Pharmaceutical compositions may also be in the form of oil-in-wateremulsions. The oily phase may be a vegetable oil, for example olive oilor peanut oil, or a mineral oil, for example liquid paraffin or mixturesof these. Suitable emulsifying agents may be naturally-occurring gums,for example gum acacia or gum tragacanth, naturally-occurringphosphatides, for example soy bean, lecithin, and esters or partialesters derived from fatty acids and hexitol, anhydrides, for examplesorbitan monoleate, and condensation products of the said partial esterswith ethylene oxide, for example polyoxyethylene sorbitan monoleate.

Dispersible powders and granules suitable for preparation of an aqueoussuspension by the addition of water provide the active ingredient inadmixture with a dispersing or wetting agent, suspending agent and oneor more preservatives. Suitable dispersing or wetting agents andsuspending agents are exemplified by those already mentioned above.

Tablets typically comprise conventional pharmaceutically acceptableadjuvants as inert diluents, such as calcium carbonate, sodiumcarbonate, mannitol, lactose and cellulose; binders such as starch,gelatin and sucrose; disintegrants such as starch, alginic acid andcroscarmelose; lubricants such as magnesium stearate, stearic acid andtalc. Glidants such as silicon dioxide can be used to improve flowcharacteristics of the powder mixture. Coloring agents, such as the FD&Cdyes, can be added for appearance. Sweeteners and flavoring agents, suchas aspartame, saccharin, menthol, peppermint, and fruit flavors, can beuseful adjuvants for chewable tablets. Capsules (including time releaseand sustained release formulations) typically comprise one or more soliddiluents disclosed above. The selection of carrier components oftendepends on secondary considerations like taste, cost, and shelfstability.

Such pharmaceutical compositions may also be coated by conventionalmethods, typically with pH or time-dependent coatings, such that thechemical entity is released in the gastrointestinal tract in thevicinity of the desired topical application, or at various times toextend the desired action. Such dosage forms typically include, but arenot limited to, one or more of cellulose acetate phthalate,polyvinylacetate phthalate, hydroxypropyl methylcellulose phthalate,ethyl cellulose, Eudragit coatings, waxes and shellac.

Pharmaceutical compositions for oral use may also be presented as hardgelatin capsules wherein the active ingredient is mixed with an inertsolid diluent, for example, calcium carbonate, calcium phosphate orkaolin, or as soft gelatin capsules wherein the active ingredient ismixed with water or an oil medium, for example peanut oil, liquidparaffin or olive oil.

Pharmaceutical compositions may be in the form of a sterile injectableaqueous or oleaginous suspension. This suspension may be formulatedaccording to the known art using those suitable dispersing or wettingagents and suspending agents that have been mentioned above. The sterileinjectable preparation may also be sterile injectable solution orsuspension in a non-toxic parentally acceptable vehicle, for example asa solution in 1,3-butanediol. Among the acceptable vehicles that may beemployed are water, Ringer's solution, and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium. For this purpose any bland fixed oilmay be employed including synthetic mono- or diglycerides. In addition,fatty acids such as oleic acid can be useful in the preparation ofinjectables.

Chemical entities described herein may be administered parenterally in asterile medium. Parenteral administration includes subcutaneousinjections, intravenous, intramuscular, intrathecal injection orinfusion techniques. Chemical entities described herein, depending onthe vehicle and concentration used, can either be suspended or dissolvedin the vehicle. Advantageously, adjuvants such as local anesthetics,preservatives and buffering agents can be dissolved in the vehicle. Inmany pharmaceutical compositions for parenteral administration thecarrier comprises at least 90% by weight of the total composition. Insome embodiments, the carrier for parenteral administration is chosenfrom propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesameoil.

Chemical entites described herein may also be administered in the formof suppositories for rectal administration of the drug. Thesepharmaceutical compositions can be prepared by mixing the drug with asuitable non-irritating excipient that is solid at ordinary temperaturesbut liquid at rectal temperature and will therefore melt in the rectumto release the drug. Such materials include cocoa butter andpolyethylene glycols.

Chemical entities described herein may be formulated for local ortopical application, such as for topical application to the skin andmucous membranes, such as in the eye, in the form of gels, creams, andlotions and for application to the eye. Topical pharmaceuticalcompositions may be in any form including, for example, solutions,creams, ointments, gels, lotions, milks, cleansers, moisturizers,sprays, skin patches, and the like.

Such solutions may be formulated as 0.01%-10% isotonic solutions, pH5-7, with appropriate salts. Chemical entities described herein may alsobe formulated for transdermal administration as a transdermal patch.

Topical pharmaceutical compositions comprising at least one chemicalentity described herein can be admixed with a variety of carriermaterials well known in the art, such as, for example, water, alcohols,aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil,propylene glycol, PPG-2 myristyl propionate, and the like.

Other materials suitable for use in topical carriers include, forexample, emollients, solvents, humectants, thickeners and powders.Examples of each of these types of materials, which can be used singlyor as mixtures of one or more materials, are as follows:

Representative emollients include stearyl alcohol, glycerylmonoricinoleate, glyceryl monostearate, propane-1,2-diol,butane-1,3-diol, mink oil, cetyl alcohol, iso-propyl isostearate,stearic acid, iso-butyl palmitate, isocetyl stearate, oleyl alcohol,isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetylalcohol, cetyl palmitate, dimethylpolysiloxane, di-n-butyl sebacate,iso-propyl myristate, iso-propyl palmitate, iso-propyl stearate, butylstearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil,coconut oil, arachis oil, castor oil, acetylated lanolin alcohols,petroleum, mineral oil, butyl myristate, isostearic acid, palmitic acid,isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, andmyristyl myristate; propellants, such as propane, butane, iso-butane,dimethyl ether, carbon dioxide, and nitrous oxide; solvents, such asethyl alcohol, methylene chloride, iso-propanol, castor oil, ethyleneglycol monoethyl ether, diethylene glycol monobutyl ether, diethyleneglycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide,tetrahydrofuran; humectants, such as glycerin, sorbitol, sodium2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, andgelatin; and powders, such as chalk, talc, fullers earth, kaolin,starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetraalkyl ammonium smectites, trialkyl aryl ammonium smectites, chemicallymodified magnesium aluminium silicate, rganically modifiedmontmorillonite clay, hydrated aluminium silicate, fumed silica,carboxyvinyl polymer, sodium carboxymethyl cellulose, and ethyleneglycol monostearate.

The chemical entities described herein may also be topicallyadministered in the form of liposome delivery systems, such as smallunilamellar vesicles, large unilamellar vesicles, and multilamellarvesicles. Liposomes can be formed from a variety of phospholipids, suchas cholesterol, stearylamine or phosphatidylcholines.

Other pharmaceutical compositions useful for attaining systemic deliveryof the chemical entity include sublingual, buccal and nasal dosageforms. Such pharmaceutical compositions typically comprise one or moreof soluble filler substances such as sucrose, sorbitol and mannitol, andbinders such as acacia, microcrystalline cellulose, carboxymethylcellulose, and hydroxypropyl methylcellulose. Glidants, lubricants,sweeteners, colorants, antioxidants and flavoring agents disclosed abovemay also be included.

Pharmaceutical compositions for inhalation typically can be provided inthe form of a solution, suspension or emulsion that can be administeredas a dry powder or in the form of an aerosol using a conventionalpropellant (e.g., dichlorodifluoromethane or trichlorofluoromethane).

The pharmaceutical compositions may also optionally comprise an activityenhancer. The activity enhancer can be chosen from a wide variety ofmolecules that function in different ways to enhance or be independentof therapeutic effects of the chemical entities described herein.Particular classes of activity enhancers include skin penetrationenhancers and absorption enhancers.

Pharmaceutical compositions may also contain additional active agentsthat can be chosen from a wide variety of molecules, which can functionin different ways to enhance the therapeutic effects of at least onechemical entity described herein. These optional other active agents,when present, are typically employed in the pharmaceutical compositionsat a level ranging from 0.01% to 15%. Some embodiments contain from 0.1%to 10% by weight of the composition. Other embodiments contain from 0.5%to 5% by weight of the composition.

Also provided are packaged pharmaceutical compositions. Such packagedcompositions include a pharmaceutical composition comprising at leastone chemical entity described herein, and instructions for using thecomposition to treat a subject (typically a human patient). In someembodiments, the instructions are for using the pharmaceuticalcomposition to treat a subject suffering a condition or disordermediated by Kynurenine 3-mono-oxygenase activity. The packagedpharmaceutical composition can include providing prescribinginformation; for example, to a patient or health care provider, or as alabel in a packaged pharmaceutical composition. Prescribing informationmay include for example efficacy, dosage and administration,contraindication and adverse reaction information pertaining to thepharmaceutical composition.

In all of the foregoing the chemical entities can be administered alone,as mixtures, or in combination with other active agents.

The methods described herein include methods for treating Huntington'sdisease, including treating memory and/or cognitive impairmentassociated with Huntington's disease, comprising administering to asubject, simultaneously or sequentially, at least one chemical entitydescribed herein and one or more additional agents used in the treatmentof Huntington's disease such as, but not limited to, Amitriptyline,Imipramine, Despiramine, Nortriptyline, Paroxetine, Fluoxetine,Setraline, Terabenazine, Haloperidol, Chloropromazine, Thioridazine,Sulpride, Quetiapine, Clozapine, and Risperidone. In methods usingsimultaneous administration, the agents can be present in a combinedcomposition or can be administered separately. As a result, alsoprovided are pharmaceutical compositions comprising at least onechemical entity described herein and one or more additionalpharmaceutical agents used in the treatment of Huntington's disease suchas, but not limited to, Amitriptyline, Imipramine, Despiramine,Nortriptyline, Paroxetine, Fluoxetine, Setraline, Terabenazine,Haloperidol, Chloropromazine, Thioridazine, Sulpride, Quetiapine,Clozapine, and Risperidone. Similarly, also provided arepackagedpharmaceutical compositions containing a pharmaceutical compositioncomprising at least one chemical entity described herein, and anothercomposition comprising one or more additional pharmaceutical agents usedin the treatment of Huntington's disease such as, but not limited to,Amitriptyline, Imipramine, Despiramine, Nortriptyline, Paroxetine,Fluoxetine, Setraline, Terabenazine, Haloperidol, Chloropromazine,Thioridazine, Sulpride, Quetiapine, Clozapine, and Risperidone.

Also provided are methods for treating Parkinson's disease, includingtreating memory and/or cognitive impairment associated with Parkinson'sdisease, comprising administering to a subject, simultaneously orsequentially, at least one chemical entity described herein and one ormore additional agents used in the treatment of Parkinson's disease suchas, but not limited to, Levodopa, Parlodel, Permax, Mirapex, Tasmar,Contan, Kemadin, Artane, and Cogentin. In methods using simultaneousadministration, the agents can be present in a combined composition orcan be administered separately. Also provided are pharmaceuticalcompositions comprising at least one chemical entity described herein,and one or more additional pharmaceutical agents used in the treatmentof Parkinson's disease, such as, but not limited to, Levodopa, Parlodel,Permax, Mirapex, Tasmar, Contan, Kemadin, Artane, and Cogentin. Alsoprovided are packaged pharmaceutical compositions containing apharmaceutical composition comprising at least one chemical entitydescribed herein, and another composition comprising one or moreadditional pharmaceutical agents gent used in the treatment ofParkinson's disease such as, but not limited to, Levodopa, Parlodel,Permax, Mirapex, Tasmar, Contan, Kemadin, Artane, and Cogentin.

Also provided are methods for treating memory and/or cognitiveimpairment associated with Alzheimer's disease, comprising administeringto a subject, simultaneously or sequentially, at least one chemicalentity described herein and one or more additional agents used in thetreatment of Alzheimer's disease such as, but not limited to, Reminyl,Cognex, Aricept, Exelon, Akatinol, Neotropin, Eldepryl, Estrogen andCliquinol. In methods using simultaneous administration, the agents canbe present in a combined composition or can be administered separately.Also provided are pharmaceutical compositions comprising at least onechemical entity described herein, and one or more additionalpharmaceutical agents used in the treatment of Alzheimer's disease suchas, but not limited to, Reminyl, Cognex, Aricept, Exelon, Akatinol,Neotropin, Eldepryl, Estrogen and Cliquinol. Similarly, also providedare packaged pharmaceutical compositions containing a pharmaceuticalcomposition comprising at least one chemical entity described herein,and another composition comprising one or more additional pharmaceuticalagents used in the treatment of Alzheimer's disease such as, but notlimited to Reminyl, Cognex, Aricept, Exelon, Akatinol, Neotropin,Eldepryl, Estrogen and Cliquinol.

Also provided are methods for treating memory and/or cognitiveimpairment associated with dementia comprising administering to asubject, simultaneously or sequentially, at least one chemical entityand one or more additional agents used in the treatment of dementia suchas, but not limited to, Thioridazine, Haloperidol, Risperidone, Cognex,Aricept, and Exelon. In methods using simultaneous administration, theagents can be present in a combined composition or can be administeredseparately. Also provided are pharmaceutical compositions comprising atleast one chemical entity described herein, and one or more additionalpharmaceutical agents used in the treatment of dementia such as, but notlimited to, Thioridazine, Haloperidol, Risperidone, Cognex, Aricept, andExelon. Also provided are packaged pharmaceutical compositionscontaining a pharmaceutical composition comprising at least one chemicalentity described herein, and another composition comprising one or moreadditional pharmaceutical agents used in the treatment of dementia suchas, but not limited to, Thioridazine, Haloperidol, Risperidone, Cognex,Aricept, and Exelon.

Also provided are methods for treating memory and/or cognitiveimpairment associated with epilepsy comprising administering to asubject, simultaneously or sequentially, at least one chemical entitydescribed herein and one or more additional agents used in the treatmentof epilepsy such as, but not limited to, Dilantin, Luminol, Tegretol,Depakote, Depakene, Zarontin, Neurontin, Barbita, Solfeton, andFelbatol. In methods using simultaneous administration, the agents canbe present in a combined composition or can be administered separately.Also provided are pharmaceutical compositions comprising at least onechemical entity described herein, and one or more additionalpharmaceutical agents used in the treatment of epilepsy such as, but notlimited to, Dilantin, Luminol, Tegretol, Depakote, Depakene, Zarontin,Neurontin, Barbita, Solfeton, and Felbatol. Also provided are packagedpharmaceutical compositions containing a pharmaceutical compositioncomprising at least one chemical entity described herein, and anothercomposition comprising one or more additional pharmaceutical agents usedin the treatment of epilepsy such as, but not limited to, Dilantin,Luminol, Tegretol, Depakote, Depakene, Zarontin, Neurontin, Barbita,Solfeton, and Felbatol.

Also provided are methods for treating memory and/or cognitiveimpairment associated with multiple sclerosis comprising administeringto a subject, simultaneously or sequentially, at least one chemicalentity described herein and one or more additional agents used in thetreatment of multiple sclerosis such as, but not limited to, Detrol,Ditropan XL, OxyContin, Betaseron, Avonex, Azothioprine, Methotrexate,and Copaxone. In methods using simultaneous administration, the agentscan be present in a combined composition or can be administeredseparately. Also provided are pharmaceutical compositions comprising atleast one chemical entity described herein, and one or more additionalpharmaceutical agents used in the treatment of multiple sclerosis suchas, but not limited to, Detrol, Ditropan XL, OxyContin, Betaseron,Avonex, Azothioprine, Methotrexate, and Copaxone. Also provided arepackaged pharmaceutical compositions containing a pharmaceuticalcomposition comprising at least one chemical entity described herein,and another composition comprising one or more additional pharmaceuticalagents used in the treatment of multiple sclerosis such as, but notlimited to, Detrol, Ditropan XL, OxyContin, Betaseron, Avonex,Azothioprine, Methotrexate, and Copaxone.

When used in combination with one or more additional pharmaceuticalagent or agents, the described herein may be administered prior to,concurrently with, or following administration of the additionalpharmaceutical agent or agents.

The dosages of the compounds described herein depend upon a variety offactors including the particular syndrome to be treated, the severity ofthe symptoms, the route of administration, the frequency of the dosageinterval, the particular compound utilized, the efficacy, toxicologyprofile, pharmacokinetic profile of the compound, and the presence ofany deleterious side-effects, among other considerations.

The chemical entities described herein are typically administered atdosage levels and in a manner customary for KMO inhibitors. For example,the chemical entities can be administered, in single or multiple doses,by oral administration at a dosage level of generally 0.001-100mg/kg/day, for example, 0.01-100 mg/kg/day, such as 0.1-70 mg/kg/day,for example, 0.5-10 mg/kg/day. Unit dosage forms can contain generally0.01-1000 mg of at least one chemical entity described herein, forexample, 0.1-50 mg of at least one chemical entity described herein. Forintravenous administration, the compounds can be administered, in singleor multiple dosages, at a dosage level of, for example, 0.001-50mg/kg/day, such as 0.001-10 mg/kg/day, for example, 0.01-1 mg/kg/day.Unit dosage forms can contain, for example, 0.1-10 mg of at least onechemical entity described herein.

A labeled form of a chemical entity described herein can be used as adiagnostic for identifying and/or obtaining compounds that have thefunction of modulating an activity of KMO as described herein. Thechemical entities described herein may additionally be used forvalidating, optimizing, and standardizing bioassays.

By “labeled” herein is meant that the compound is either directly orindirectly labeled with a label which provides a detectable signal,e.g., radioisotope, fluorescent tag, enzyme, antibodies, particles suchas magnetic particles, chemiluminescent tag, or specific bindingmolecules, etc. Specific binding molecules include pairs, such as biotinand streptavidin, digoxin and antidigoxin etc. For the specific bindingmembers, the complementary member would normally be labeled with amolecule which provides for detection, in accordance with knownprocedures, as outlined above. The label can directly or indirectlyprovide a detectable signal.

In carrying out the procedures of the methods described herein, it is ofcourse to be understood that reference to particular buffers, media,reagents, cells, culture conditions and the like are not intended to belimiting, but are to be read so as to include all related materials thatone of ordinary skill in the art would recognize as being of interest orvalue in the particular context in which that discussion is presented.For example, it is often possible to substitute one buffer system orculture medium for another and still achieve similar, if not identical,results. Those of skill in the art will have sufficient knowledge ofsuch systems and methodologies so as to be able, without undueexperimentation, to make such substitutions as will optimally servetheir purposes in using the methods and procedures disclosed herein.

EXAMPLES

The chemical entities, compositions, and methods described herein arefurther illustrated by the following non-limiting examples.

As used herein, the following abbreviations have the following meanings.If an abbreviation is not defined, it has its generally acceptedmeaning.

-   -   CDI=carbonyldiimidazole    -   DCM=dichloromethane    -   DME=dimethyl ether    -   DMEM=Dulbecco's modified Eagle's medium    -   DMF=N,N-dimethylformamide    -   DMSO=dimethylsulfoxide    -   EDC.HCl=1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide        hydrochloride    -   EtOH=ethanol    -   Et₂O=diethylether    -   EtOAc=ethyl acetate gram    -   hr=hour    -   hrs=hours    -   HOBt=tert-butyl alcohol    -   LiHMDS=lithium hexamethyl-disilazide    -   LC/MS=liquid chomatography/mass spectrometry    -   mg=milligram    -   min=minutes    -   mL=milliliter    -   mmol=millimoles    -   mM=millimolar    -   ng=nanogram    -   nm=nanometer    -   nM=nanomolar    -   PBS=phosphate buffered saline    -   rt=room temperature    -   TBME=t-butyl methyl ether    -   THF=tetrahydrofuran    -   TMOF=trimethylorthoformate    -   μL=microliter    -   μM=micromolar

Experimental

Commercially available reagents and solvents (HPLC grade) were usedwithout further purification.

Thin-layer chromatography (TLC) analysis was performed with Kieselgel 60F₂₅₄ (Merck) plates and visualized using UV light. Microwave reactionswere carried out using CEM focussed microwaves.

Analytical HPLC-MS was performed on Agilent HP1100 and Shimadzu 2010,systems using reverse phase Atlantis dC18 columns (5 μm, 2.1×50 mm),gradient 5-100% B (A=water/0.1% formic acid, B=acetonitrile/0.1% formicacid) over 3 min, injection volume 3 μl, flow=1.0 ml/min. UV spectrawere recorded at 215 nm using a Waters 2487 dual wavelength UV detectoror the Shimadzu 2010 system. Mass spectra were obtained over the rangem/z 150 to 850 at a sampling rate of 2 scans per second using Waters ZMDand over m/z 100 to 1000 at a sampling rate of 2 Hz using Electrosprayionisation, by a Shimadzu 2010 LC-MS system or analytical HPLC-MS wasperformed on Agilent HP 1100 and Shimadzu 2010, systems using reversephase Water Atlantis dC18 columns (3 μm, 2.1×100 mm), gradient 5-100% B(A=water/0.1% formic acid, B=acetonitrile/0.1% formic acid) over 7 min,injection volume 3 μl, flow=0.6 ml/min. UV spectra were recorded at 215nm using a Waters 2996 photo diode array or on the Shimadzu 2010 system.Mass spectra were obtained over the range m/z 150 to 850 at a samplingrate of 2 scans per second using Waters ZQ and over m/z 100 to 1000 at asampling rate of 2 Hz using Electrospray ionisation, by a Shimadzu 2010LC-MS system. Data were integrated and reported using OpenLynx andOpenLynx Browser software or via Shimadzu PsiPort software.

1 g/1 ml=1 vol

General Procedures

Method A. Amide coupling. To a solution of carboxylic acid (1 eq) in DMFwere added EDC.HCl (1 eq) and HOBt (1 eq). The reaction mixture wasstirred at ambient temperature for 30 minutes after which time theappropriate amine was added. The reaction was monitored by LCMS. Aftercompletion the reaction mixture was poured into water after which aprecipitate came out of solution and was filtered, washed with water,heptane and dried in vacuo to yield the target compound or if aprecipitate was not formed the reaction mixture was extracted with EtOAc(3×) and the combined organic layers were washed with water, saturatedaqueous NaCl, dried (Na₂SO₄ or MgSO₄) and the solvent removed in vacuoto afford the crude product. Purification was carried out by flashcolumn chromatography, prep HPLC, or a combination of both.

Method B. Amide coupling. To a solution of carboxylic acid (1 eq) in DCM(20 vol) under nitrogen were added oxalyl chloride (3 eq) and 1 drop ofDMF (cat.). The reaction mixture was stirred at ambient temperature for30 minutes after which time the solvents were removed in vacuo. DCM (20vol) or THF (20 vol) was added, followed by the required amine (1 to 3eq) and triethylamine (2 eq) and the reaction mixture was stirred atambient temperature. The reaction was monitored by LCMS to completionwhereupon water was added. The reaction mixture was then extracted withDCM and the organic layer was washed with water, saturated aqueous NaCl,dried over Na₂SO₄ or MgSO₄ and the solvent removed in vacuo to affordthe crude product. Purification was carried out by flash columnchromatography, prep HPLC, a combination of both or by trituration withan appropriate solvent.

Example 1

Preparation of Pyrimidine Analogues

Stage 1

To a stirred suspension of dichloropyrimidine (1 eq) in 1,4-dioxane (15vol) was added boronic acid (0.7 eq) and Pd(PPh₃)₄ (0.025 eq). A 2MK₂CO₃ solution (7.5 vol) was added to the resulting mixture, which washeated at 90° C. overnight under an atmosphere of N₂. The reactionmixture was cooled to room temperature and concentrated in vacuo. Theresidue was dissolved in EtOAc:water (1:1) (100 vol) and the resultingsolution filtered through celite. The organic layer was separated andthe aqueous layer further extracted with EtOAc (50 vol). The combinedorganic layers were washed with saturated aqueous NaCl (20 vol), driedover Na₂SO₄, filtered and the solvent removed in vacuo. The resultingresidue was purified by flash column chromatography (eluent: [0:1 to1:19] EtOAc:heptane) to afford the required target compounds.

Stage 2

4-Chloro-6-substituted-phenyl-pyrimidine (1 eq), PdCl₂(dppf). DCM (0.05eq) and triethylamine (2 eq) were suspended in degassed MeOH (50 vol) ina bomb fitted with a magnetic stirrer bar. The atmosphere in thereaction vessel was replaced with N₂ by successive evacuation andcharging with N₂ gas (this process was repeated three times). The bombwas then flushed with CO by successive charging with CO and evacuation.The vessel was pressurised to 5 bar of CO and heated at 50° C. withstirring for 5 hours. The reaction vessel was allowed to cool to roomtemperature before venting CO and flushing with N₂. The reaction mixturewas concentrated in vacuo and the resulting residue dissolved in EtOAc(30 vol) and water (30 vol). The solution was filtered through cottonwool and the organic layer was separated, washed with saturated aqueousNaCl (15 vol), dried over Na₂SO₄, filtered and concentrated underreduced pressure. Purification by flash column chromatography (eluent:[0:1 to 1:9] EtOAc:heptane) yielded the target compounds.

Stage 3

6-Substituted-phenyl-pyrimidine-4-carboxylic acid methyl ester (1 eq)was suspended in MeOH (20 vol), 1M NaOH solution (20 vol) and stirred atroom temperature for 4 hours. The reaction mixture was acidified with 2MHCl. Soluble products were extracted with DCM (2×20 vol) and thecombined organic layers were dried over MgSO₄, filtered andconcentration under reduced pressure afforded the target compounds.Insoluble products were filtered, washed with water (3×10 vol) andheptane (3×10 vol) before drying in vacuo to yield the target compounds.

Stage 4

The required amide analogues were prepared following the proceduresdescribed in method A or B.

Example 2

Step 1

4-Chloro-6-substituted-phenyl-pyrimidine (1 eq) was suspended inammonium hydroxide (60 vol) before irradiation at 100° C. in a microwavefor 1 hour with stirring. The reaction mixture was extracted with DCM(5×20 vol). Solvent was removed in vacuo to yield the target compound.

Step 2

6-Substituted-phenyl-pyrimidin-4-ylamine (1 eq) was suspended in dioxane(30 vol). Sodium hydride (3 to 10 eq) was added and the suspensionstirred for 30 minutes at room temperature. The corresponding sulfonylchloride (1.1 eq) was added and the reaction mixture stirred at roomtemperature for 1 to 5 days. The reaction was quenched by the additionof water (40 vol), EtOAc (40 vol) was added and the mixture partitioned.The aqueous layer was washed with EtOAc (3×20 vol) and the organic layerdiscarded. The aqueous layer was then acidified to =pH1 withconcentrated HCl and extracted with EtOAc (4×40 vol). The combinedorganic layers were washed with saturated aqueous NaCl solution (40vol), dried over Na₂SO₄, filtered and concentrated in vacuo to affordthe target compounds.

Step 3

6-Substituted-phenyl-pyrimidin-4-ylamine (1 eq) was suspended in dioxane(20 vol). Sodium hydride (4 eq) was added and the suspension stirred for30 minutes at room temperature. The corresponding acid chloride (1.1 eq)was added and the reaction mixture stirred at room temperature for 3days. A further addition of sodium hydride (4 eq) was required and thereaction mixture stirred at room temperature for 24 h. The reaction wasquenched by the addition of water (75 vol), and acidified with HCl (topH1). The acidic solution was extracted with DCM (2×50 vol). Thecombined organic layers were washed with saturated aqueous NaCl solution(50 vol), dried over Na₂SO₄, filtered and concentrated in vacuo. Theresidue was recrystallised from hot MeOH to afford the target compound.

Example 3

To a stirred solution of 6-(3-chloro-phenyl)-pyrimidine-4-carboxylicacid amide (1 eq) in DMF (25 vol) was added sodium hydride (1.1 eq). Thereaction mixture was stirred at ambient temperature for 30 mins andmethyl iodide (2 eq) was added. The reaction mixture was stirred atambient temperature for 3 to 4 hours. Water was added and the mixturewas extracted with ethyl acetate or DCM. The organic layer was washedwith water and brine, dried over MgSO₄, filtered and the solvent removedin vacuo to furnish the crude amide, which was further purified by flashcolumn chromatography or prep HPLC.

Example 4

To a stirred solution of 6-(3-chloro-phenyl)-pyrimidine-4-carboxylicacid (1 eq) or 6-(3,4-dichloro-phenyl)-pyrimidine-4-carboxylic acidmethyl ester in THF (20 vol) was added dropwise a 1M NaOH solution. Themixture was stirred at ambient temperature and the resulting precipitatewas filtered and washed with water/THF or with water then heptane tofurnish the described salts.

Example 5

To a stirred solution of 6-(3-chloro-phenyl)-pyrimidine-4-carboxylicacid (1 eq) dissolved in the minimum amount of THF was addedcyclohexylamine. The mixture was stirred at ambient temperature for 1hour and the resulting precipitate was filtered and washed with THF tofurnish the described salt.

Example 6

To a stirred suspension of 6-(3-chloro-phenyl)-pyrimidine-4-carboxylicacid pyridin-3-ylamide (1 eq) in methanol was added 6N HCl at ambienttemperature. After complete dissolution was observed, the solvents wereremoved in vacuo and the resulting salt was purified by successivetrituration with acetone and tert-butylmethylether. Re-crystallisationfrom ethanol afforded the desired compound.

Example 7

Stage 1

To a stirred solution of 6-(substituted-phenyl)-pyrimidine-4-carboxylicacid (1 eq) in DCM (20 vol) under an atmosphere of nitrogen were addedoxalyl chloride (3 eq) and 1 drop of DMF (cat.). The reaction mixturewas stirred at ambient temperature for 30 minutes after which time thesolvents were removed in vacuo. The resulting residue was used in thenext stage without further purification.

Stage 2

The resulting residue was dissolved in THF (10 vol). Triethylamine (1eq) and the appropriate sulfonamide (1.5 eq) were added to the reactionmixture, which was stirred at ambient temperature for 4 to 16 hours. Thesolvent was removed in vacuo and the resulting residue was purified bytrituration with water and diethyl ether. The solid was filtered andwashed with water and DCM. When precipitation did not happen, thesolvent was removed in vacuo and DCM was added. The organic phase waswashed with a saturated solution of sodium bicarbonate followed by a 2Msolution of citric acid, dried with Na₂SO₄, filtered and the solventremoved in vacuo to furnish the crude compound, which was purified byflash column chromatography (eluent: [1:10] to [1:0] EtOAc:heptane) tofurnish the desired target compound.

Example 8

Stage 1

To a stirred solution of formamidine acetate (1 eq) in ethanol (50 vol)was added a solution of sodium ethoxide in ethanol (2% w/w) (3 eq) at 0°C. and the reaction mixture was stirred at that temperature for 30minutes. To the resulting mixture was added a solution of diethylfluoromalonate (1 eq) in ethanol (5 vol) and the reaction mixture wasstirred at ambient temperature for 72 hours. The reaction mixture wascooled to 0° C. and concentrated HCl (3 vol) was added to adjust the pHof the reaction mixture to pH6. The resulting precipitate was filtered,washed with isopropanol, diethylether and hexane to furnish the desiredintermediate, which was used in the next stage without furtherpurification.

Stage 2

To a stirred solution of N,N-dimethylaniline (1 eq) in phosphorousoxychloride (4 vol) was added 5-fluoro-pyrimidine-4,6-diol (1 eq) andthe reaction mixture was heated at reflux for 16 hours. After cooling toroom temperature the solvent was removed in vacuo and the resultingresidue was poured into ice. The desired intermediate was then extractedwith EtOAc. The organic layer was dried with MgSO₄, filtered and thesolvent removed in vacuo to furnish the desired intermediate, which wasused in the next stage without further purification.

Stage 3

4,6-Dichloro-5-fluoro-pyrimidine (1 eq), 3,4-dichlorophenyl boronic acid(0.7 eq) and Pd(PPh₃)₄ (0.05 eq) were suspended in 1,4-dioxane (20 vol).A 2M K₂CO₃ solution (6.75 vol) was added and the reaction mixture washeated at 90° C. with stirring for 2 hours under an atmosphere of N₂.The reaction mixture was cooled to room temperature and concentrated invacuo. The residue was dissolved in EtOAc and water. The mixture waspartitioned and the aqueous layer further extracted with EtOAc. Thecombined organic layers were washed with saturated aqueous NaCl, driedover Na₂SO₄, filtered and the solvent removed in vacuo. The resultingresidue was purified by flash column chromatography (eluent: [1:15]EtOAc:heptane) to afford the required target compound.

Stage 4

4-Chloro-6-(3,4-dichloro-phenyl)-5-fluoro-pyrimidine (1 eq),PdCl₂(dppf). DCM (0.05 eq) and triethylamine (2 eq) were suspended indegassed MeOH (50 vol) in a bomb fitted with a magnetic stirrer bar. Theatmosphere in the reaction vessel was replaced with N₂ by successiveevacuation and charging with N₂ gas (this process was repeated threetimes). The bomb was then flushed with CO by successive charging with COand evacuation. The vessel was pressurised to 5 bar of CO and heated at50° C. with stirring for 5 hours. The reaction vessel was allowed tocool to room temperature before venting CO and flushing with N₂. Thereaction mixture was concentrated in vacuo. Purification of the residueby flash column chromatography (eluent: [1:15] EtOAc:heptane) yieldedthe target compound.

Stage 5

6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acid methylester (1 eq) was suspended in THF (30 vol), 2M NaOH solution (5 eq) andstirred at room temperature for 3 hours. The reaction mixture wasconcentrated in vacuo. The resulting residue was dissolved in EtOAc andwater. The aqueous layer was separated and the precipitate removed byfiltration. The aqueous layer was acidified with cone. HCl and theresulting precipitate was filtered and washed with water to furnish thedesired target compound.

Stage 6

The required amide analogues were prepared following the proceduredescribed in method B and were purified by trituration inacetonitrile/water (1/1).

Example 9

Stage 1

2-Chloro-isonicotinic acid (1 eq), 3-chlorophenyl boronic acid (1.5 eq)and Pd(PPh₃)₄ (0.03 eq) were suspended in 1,4-dioxane (20 vol). A 2MK₂CO₃ solution (7.5 vol) was added to the reaction mixture, which washeated at 90° C. with stirring for 16 hours under an atmosphere of N₂.3-Chlorophenyl boronic acid (0.5 eq), Pd(PPh₃)₄ (0.03 eq) and a 2M K₂CO₃solution (7.5 vol) were added to the reaction mixture, which was heatedat 90° C. for a further hour. The reaction mixture was cooled to roomtemperature and washed with EtOAc and dichloromethane. The aqueous layerwas acidified with concentrated HCl and the resulting precipitate wasisolated by filtration and used in the next step without furtherpurification.

Stage 2

To a stirred suspension of the intermediate obtained in Stage 1 inmethanol (50 vol) was added concentrated HCl (4 drops) and the reactionmixture was stirred at 65° C. for 16 hours. The reaction mixture wasconcentrated in vacuo. The resulting residue was dissolved in DCM andwater. The organic phase was collected and the solvent was removed invacuo. Purification by flash column chromatography (eluent: [1:20]EtOAc:heptane), followed by prep HPLC yielded the target compound.

Stage 3

To a stirred solution of 2-(3-chloro-phenyl)-isonicotinic acid methylester (1 eq) in THF (30 vol) was added 2M NaOH solution (8 vol) and thereaction mixture was stirred at ambient temperature for 3 hours. Thereaction mixture was concentrated in vacuo. The residue was dissolved ina 2M solution of HCl and the resulting precipitate was filtered off andwashed with water and heptane to furnish the desired target compound.

Example 10

Stage 1

To a stirred suspension of 4-bromo-pyridine-2-carboxylic acid methylester (1 eq) in 1,4-dioxane (20 vol) was added the appropriatesubstituted phenyl boronic acid (1.1 eq) and Pd(PPh₃)₄ (0.05 eq). A 2MK₂CO₃ solution (7.5 vol) was added and the reaction mixture was heatedat 90° C. with stirring for 16 hours under an atmosphere of N₂. Thereaction mixture was cooled to room temperature and the resultingprecipitate was isolated by filtration to furnish the acid intermediateas the potassium salt, which was used without further purification inthe stage. In the case of the 3-chlorophenyl analogue no precipitate wasformed upon cooling, hence the solvent was removed in vacuo. Theresulting residue was dissolved in EtOAc and water. Both phases wereseparated. EtOAc was removed in vacuo and the resulting residue waspurified by flash column chromatography (eluent: [5:95] methanol:DCM) tofurnish the desired 4-(3-chloro-phenyl)-pyridine-2-carboxylic acidmethyl ester. The aqueous phase was acidified and the resultingprecipitate was isolated by filtration and used as such in stage 2.Further purification was carried out by prep HPLC to furnish therequired 4-(3-chloro-phenyl)-pyridine-2-carboxylic acid.

Stage 2

The required amide analogues were prepared following the proceduredescribed in method A from 4-(3-chloro-phenyl)-pyridine-2-carboxylicacid, hydrochloride salt and were purified by trituration inacetonitrile/water (1/1) or in water followed by heptane.

Stage 3

The potassium salt isolated in stage 1 was suspended in HCl (2M) andstirred at ambient temperature for 2 hours. The solid was filtered andwashed with water to furnish the desired target compound.

Stage 4

The required amide analogues were prepared following the proceduredescribed in method A from 4-(substituted-phenyl)-pyridine-2-carboxylicacid potassium salt and were purified by trituration inacetonitrile/water (1/1) or in water followed by heptane.

Example 11

The following compounds were prepared substantially as described above.

IUPAC name Mass Spec Result 6-(2-Trifluoromethyl-phenyl)-pyrimidine-[M + H]⁺ = 283, 94% @ rt = 3.90 min 4-carboxylic acid methyl ester6-(2-Trifluoromethyl-phenyl)-pyrimidine- [M + H]⁺ = 269, 100% @ rt =3.34 min 4-carboxylic acid N-[6-(2-Trifluoromethyl-phenyl)- [M + H]⁺ =311, 98% @ rt = 4.00 min pyrimidin-4-yl]-methanesulfonamide3,4-Dimethoxy-N-[6-(2-trifluoromethyl- [M + H]⁺ = 318, 98% @ rt = 3.92min phenyl)-pyrimidin-4-yl]- benzenesulfonamideN-[6-(3,4-Dichloro-phenyl)-pyrimidin-4- [M + H]⁺ = 440, 100% @ rt = 4.41min yl]-methanesulfonamide 6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M +H]⁺ = 283, 100% @ rt = 4.47 min carboxylic acid methyl esterN-[6-(3,4-Dichloro-phenyl)-pyrimidin-4- [M + H]⁺ = 440, 100% @ rt = 3.88min yl]-3,4-dimethoxy-benzenesulfonamide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 249, 97% @ rt = 3.98 mincarboxylic acid methyl ester 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺= 235, 100% @ rt = 3.66 min carboxylic acid6-(3-chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 235, 89% @ rt = 3.93 mincarboxylic acid sodium salt 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ =235, 92% @ rt = 3.84 min carboxylic acid cyclohexyl ammonium salt6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 345, 95% @ rt = 4.17min carboxylic acid pyridin-3-ylamide 6-(3-Chloro-phenyl)-pyrimidine-4-[M + H]⁺ = 311, 100% @ rt = 3.74 min carboxylic acid pyridin-3-ylamide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 311, 100% @ rt 3.73 mincarboxylic acid pyridin-3-ylamide hydrochloride salt6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 269, 100% @ rt = 4.04min carboxylic acid 6-(3,4-dichloro-phenyl)-pyrimidine-4- [M + H]⁺ =269/271, 100% @ rt = 4.17 min carboxylic acid sodium salt6-(3,5-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 269, 99% @ rt = 4.30min carboxylic acid 6-(3,5-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ =283, 99% @ rt = 4.58 min carboxylic acid methyl esterN-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 318, 94% @ rt = 3.39min nicotinamide 6-(3,4-Dichloro-phenyl)-2-methyl- [M + H]⁺ = 297, 100%@ rt = 4.78 min pyrimidine-4-carboxylic acid methyl ester6-(3,4-Dichloro-phenyl)-2-methyl- [M + H]⁺ = 283, 99% @ rt = 4.43 minpyrimidine-4-carboxylic acid 6-(3,4-Dichloro-phenyl)-2-methyl- [M + H]⁺= 359, 100% @ rt = 4.50 min pyrimidine-4-carboxylic acid pyridin-3-ylamide 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 339, 100% @ rt =3.17 min carboxylic acid (2,6-dimethyl-pyridin-3- yl)-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 312, 98% @ rt = 4.00 mincarboxylic acid pyrimidin-5-ylamide6-(4-Morpholin-4-yl-phenyl)-pyrimidine-4- [M + H]⁺ = 300, 96% @ rt =3.61 min carboxylic acid methyl ester6-(4-Fluoro-3-trifluoromethyl-phenyl)- [M + H]⁺ = 300, 95% @ rt = 4.39min pyrimidine-4-carboxylic acid methyl ester6-(3-Trifluoromethyl-phenyl)-pyrimidine- [M + H]⁺ = 282, 97% @ rt = 4.16min 4-carboxylic acid methyl ester6-(4-Fluoro-3-trifluoromethyl-phenyl)- [M + H]⁺ = 286, 100% @ rt = 4.07min pyrimidine-4-carboxylic acid6-(3-Trifluoromethyl-phenyl)-pyrimidine- [M + H]⁺ = 345, 100% @ rt =4.92 min 4-carboxylic acid pyridin-2-ylamide6-(4-Fluoro-3-trifluoromethyl-phenyl)- [M + H]⁺ = 363, 99% @ rt = 4.06min pyrimidine-4-carboxylic acid pyridin-3- ylamide6-(3,5-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 344, 100% @ rt = 4.38min carboxylic acid pyridin-3-ylamide6-(3-Trifluoromethyl-phenyl)-pyrimidine- [M + H]⁺ = 344, 100% @ rt =3.89 min 4-carboxylic acid pyridin-3-ylamide6-(3-Trifluoromethyl-phenyl)-pyrimidine- [M + H]⁺ = 268, 100% @ rt =3.78 min 4-carboxylic acid 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ =262, 99% @ rt = 4.34 min carboxylic acid ethylamide6-(5-Fluoro-pyridin-3-yl)-pyrimidine-4- [M + H]⁺ = 219, 99% @ rt = 2.66min carboxylic acid 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 234,100% @ rt = 3.60 min carboxylic acid amide6-(3-Fluoro-5-trifluoromethyl-phenyl)- [M + H]⁺ = 300, 100% @ rt = 4.52min pyrimidine-4-carboxylic acid methyl ester6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 248, 100% @ rt = 3.85 mincarboxylic acid methylamide 6-(5-Fluoro-pyridin-3-yl)-pyrimidine-4- [M +H]⁺ = 233, 100% @ rt = 2.96 min carboxylic acid methyl ester6-(3-Fluoro-5-trifluoromethyl-phenyl)- [M + H]⁺ = 286, 97% @ rt = 4.26min pyrimidine-4-carboxylic acid 6-(5-Chloro-pyridin-3-yl)-pyrimidine-4-[M + H]⁺ = 249, 100% @ rt = 3.30 min carboxylic acid methyl ester6-(5-Chloro-pyridin-3-yl)-pyrimidine-4- [M + H]⁺ = 236, 100% @ rt = 2.92min carboxylic acid 6-(2-Fluoro-5-trifluoromethyl-phenyl)- [M + 23]⁺ =301, 100% @ rt = 4.17 min pyrimidine-4-carboxylic acid methyl ester6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 275, 99% @ rt = 4.68 mincarboxylic acid isopropylamide [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-[M + H]⁺ = 304, 100% @ rt = 3.64 min morpholin-4-yl-methanone6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 276, 100% @ rt = 4.39 mincarboxylic acid propylamide 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ =309, 100% @ rt = 5.17 min carboxylic acid phenylamide6-Pyridin-3-yl-pyrimidine-4-carboxylic [M + H]⁺ = 216, 100% @ rt = 2.27min acid methyl ester trifluoroacetic acid salt6-Phenyl-pyrimidine-4-carboxylic acid [M + H]⁺ = 201, 100% @ rt = 3.29min 6-(2-Fluoro-5-trifluoromethyl-phenyl)- [M + H]⁺ = 286, 100% @ rt =4.03 min pyrimidine-4-carboxylic acid 6-(3-Chloro-phenyl)-pyrimidine-4-[M + H]⁺ = 324, 100% @ rt = 5.08 min carboxylic acid o-tolylamide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 323, 100% @ rt = 5.40 mincarboxylic acid p-tolylamide [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(3,4-[M + H]⁺ = 350/352, 100% @ rt = 4.57 mindihydro-2H-quinolin-1-yl)-methanone 6-Phenyl-pyrimidine-4-carboxylicacid [M + H]⁺ = 215, 99% @ rt = 3.55 min methyl ester6-(2,4-Difluoro-phenyl)-pyrimidine-4- [M + H]⁺ = 251, 98% @ rt = 3.76min carboxylic acid methyl ester 6-(2,4-Difluoro-phenyl)-pyrimidine-4-[M + H]⁺ = 237, 100% @ rt = 3.41 min carboxylic acid6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 341, 100% @ rt = 4.53 mincarboxylic acid (6-methoxy-pyridin-3-yl)- amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(2,3- [M + H]⁺ = 336, 100% @ rt =4.57 min dihydro-indol-1-yl)-methanone 6-(3-Chloro-phenyl)-pyrimidine-4-[M + H]⁺ = 324, 100% @ rt = 5.25 min carboxylic acid m-tolylamide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 325, 100% @ rt = 3.71 mincarboxylic acid methyl-pyridin-3-yl-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 341, 100% @ rt = 4.15 mincarboxylic acid (5-methoxy-pyridin-3-yl)- amide6-(3-Chloro-2-fluoro-phenyl)-pyrimidine- [M + H]⁺ = 267, 100% @ rt =3.99 min 4-carboxylic acid methyl ester6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 262, 100% @ rt = 3.73 mincarboxylic acid dimethylamide 6-(3-Chloro-phenyl)-2-methyl-pyrimidine-[M + H]⁺ = 262, 99% @ rt = 4.48 min 4-carboxylic acid methyl ester4-[6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 317, 100% @ rt = 3.30min carbonyl]-piperazin-2-one 6-Phenyl-pyrimidine-4-carboxylic acid [M +H]⁺ = 277, 100% @ rt = 3.30 min pyridin-3-ylamide6-(3-Chloro-2-fluoro-phenyl)-pyrimidine- [M + H]⁺ = 253, 97% @ rt = 3.96min 4-carboxylic acid 6-(3,4-Dichloro-phenylamino)-pyrimidine- [M + H]⁺= 297, 100% @ rt = 4.21 min 4-carboxylic acid methyl ester6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 341, 99% @ rt = 3.19 mincarboxylic acid (4-methoxy-pyridin-3-yl)- amide6-(3-Chloro-phenyl)-2-methyl-pyrimidine- [M + H]⁺ = 249, 100% @ rt =3.88 min 4-carboxylic acid 6-(3-Chloro-phenyl)-2-methyl-pyrimidine- [M +H]⁺ = 325, 100% @ rt = 4.14 min 4-carboxylic acid pyridin-3-ylamide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 278, 100% @ rt = 3.56 mincarboxylic acid (2-hydroxy-ethyl)-amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(4- [M + H]⁺ = 318, 100% @ rt =3.42 min hydroxy-piperidin-1-yl)-methanone6-(3-Methoxy-phenyl)-pyrimidine-4- [M + H]⁺ = 231, 100% @ rt = 3.20 mincarboxylic acid 6-(3-Methoxy-phenyl)-pyrimidine-4- [M + H]⁺ = 245, 99% @rt = 3.80 min carboxylic acid methyl ester6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 324, 100% @ rt = 4.97 mincarboxylic acid benzylamide 6-Morpholin-4-yl-pyrimidine-4-carboxylic[M + H]⁺ = 210, 100% @ rt 1.02 min - acid hydochloride salt LCMS profileof distorted appearance [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(4- [M +H]⁺ = 317, 100% @ rt = 2.66 min methyl-piperazin-1-yl)-methanone[6-(3-Chloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 287, 100% @ rt = 4.56min pyrrolidin-1-yl-methanone 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺= 292, 100% @ rt = 3.78 min carboxylic acid ((S)-2-hydroxy-propyl)-amide 6-m-Tolyl-pyrimidine-4-carboxylic acid [M + H]⁺ = 229, 100% @ rt =4.06 min methyl ester 1-{4-[6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ =345, 100% @ rt = 3.51 min carbonyl]-piperazin-1-yl}-ethanone6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 292, 100% @ rt = 3.77 mincarboxylic acid ((R)-2-hydroxy-propyl)- amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 340, 100% @ rt = 5.45 mincarboxylic acid (2-methoxy-phenyl)-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 339, 100% @ rt = 5.43 mincarboxylic acid (4-methoxy-phenyl)-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 340, 100% @ rt = 5.16 mincarboxylic acid (3-methoxy-phenyl)-amide Sodium;6-(3-chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 271, 96.9% @ rt = 3.13 minsulfonate 6-m-Tolyl-pyrimidine-4-carboxylic acid [M + H]⁺ = 215, 100% @rt = 3.90 min 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 324, 100% @rt = 4.48 min carboxylic acid methyl-phenyl-amide[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 369, 100% @ rt =5.38 min (2,3-dihydro-indol-1-yl)-methanoneN-[6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 311/313, 100% @ rt =4.08 min carbonyl]-methanesulfonamide 6-(3-Chloro-phenyl)-pyrimidine-4-[M + H]⁺ = 310, 100% @ rt = 4.98 min carboxylic acid pyridin-2-ylamide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 310, 100% @ rt = 3.08 mincarboxylic acid pyridin-4-ylamide 6-(3-Chloro-phenyl)-pyrimidine-4- [M +H]⁺ = 324, 97% @ rt = 2.98 min carboxylic acid(pyridin-4-ylmethyl)-amide [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(4- [M +H]⁺ = 316, 97% @ rt = 4.64 min methyl-piperidin-1-yl)-methanone[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-((R)- [M + H]⁺ = 304, 100% @ rt =3.48 min 3-hydroxy-pyrrolidin-1-yl)-methanone6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 317, 100% @ rt = 4.18 mincarboxylic acid [1,3,4]thiadiazol-2-ylamide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 300, 93% @ rt = 4.48 mincarboxylic acid isoxazol-3-ylamide 6-(3-Chloro-phenyl)-pyrimidine-4-[M + H]⁺ = 338, 100% @ rt = 5.11 min carboxylic acid((R)-1-phenyl-ethyl)-amide 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ =338, 100% @ rt = 5.10 min carboxylic acid ((S)-1-phenyl-ethyl)-amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-((S)- [M + H]⁺ = 304, 100% @ rt =3.48 min 3-hydroxy-pyrrolidin-1-yl)-methanone6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 408, 99% @ rt = 3.30 mincarboxylicacid[4-(4-methyl-piperazin-1- yl)-phenyl]-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 378, 100% @ rt = 5.13 mincarboxylic acid (6-trifluoromethyl-pyridin- 3-yl)-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 324, 100% @ rt = 3.15 mincarboxylic acid (pyridin-3-ylmethyl)-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 311, 100% @ rt = 4.36 mincarboxylic acid pyridazin-3-ylamide 6-(3-Chloro-phenyl)-pyrimidine-4-[M + H]⁺ = 311, 98% @ rt = 4.67 min carboxylic acid pyrazin-2-ylamide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 395, 100% @ rt = 4.91 mincarboxylic acid (4-morpholin-4-yl-phenyl)- amide(S)-1-[6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 331, 100% @ rt =3.39 min carbonyl]-pyrrolidine-2-carboxylic acid amide(R)-1-[6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 331, 99% @ rt = 3.41min carbonyl]-pyrrolidine-2-carboxylic acid amideAzetidin-1-yl-[6-(3-chloro-phenyl)- [M + H]⁺ = 273, 100% @ rt = 4.25 minpyrimidin-4-yl]-methanone 6-(4-Methoxy-phenyl)-pyrimidine-4- [M + H]⁺ =231, 100% @ rt = 3.52 min carboxylic acid[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(1,3- [M + H]⁺ = 335, 100% @ rt =5.32 min dihydro-isoindol-2-yl)-methanone[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 384, 100% @ rt =5.13 min (3,4-dihydro-2H-quinolin-1-yl)-methanone6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 344, 100% @ rt = 5.41min carboxylic acid phenylamide 6-(3,4-Dichloro-phenyl)-pyrimidine-4-[M + H]⁺ = 358, 100% @ rt = 5.61 min carboxylic acid p-tolylamide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 374, 100% @ rt = 4.67min carboxylic acid (5-methoxy-pyridin-3-yl)- amide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 346, 100% @ rt = 4.47min carboxylic acid pyrimidin-5-ylamide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 360, 100% @ rt = 3.82min carboxylic acid (6-methyl-pyridin-3-yl)- amide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 358, 100% @ rt = 3.76min carboxylic acid (6-methyl-pyridin-3-yl)- amide hydrochloride salt6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 360, 100% @ rt = 4.09min carboxylic acid (2-methyl-pyridin-3-yl)- amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 312, 100% @ rt = 4.12 mincarboxylic acid pyrimidin-2-ylamide 6-(3-Chloro-phenyl)-pyrimidine-4-[M + H]⁺ = 338, 100% @ rt = 4.68 min carboxylic acidmethyl-p-tolyl-amide 6-(3-Fluoro-phenyl)-pyrimidine-4- [M + H]⁺ = 232,100% @ rt = 3.87 min carboxylic acid methyl ester6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 325, 100% @ rt = 3.39 mincarboxylic acid (6-methyl-pyridin-3-yl)- amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 325, 100% @ rt = 3.63 mincarboxylic acid (2-methyl-pyridin-3-yl)- amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 327, 100% @ rt = 5.25 mincarboxylic acid (4-fluoro-phenyl)-amide6-(3-Fluoro-phenyl)-pyrimidine-4- [M + H]⁺ = 219, 100% @ rt = 3.54 mincarboxylic acid 6-(3,5-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 344,100% @ rt = 5.47 min carboxylic acid phenylamide[6-(3,5-Dichloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 369, 100% @ rt =5.38 min (2,3-dihydro-indol-1-yl)-methanone6-(3,5-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 358, 100% @ rt = 5.67min carboxylic acid p-tolylamide 6-(3,5-Dichloro-phenyl)-pyrimidine-4-[M + H]⁺ = 375, 100% @ rt = 4.75 min carboxylic acid(5-methoxy-pyridin-3-yl)- amide 6-(3-Chloro-phenyl)-pyrimidine-4- [M +H]⁺ = 314, 100% @ rt = 4.39 min carboxylic acid (1-methyl-1H-pyrazol-3-yl)-amide 6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 313, 99% @ rt =4.15 min carboxylic acid (1-methyl-1H-pyrazol-4- yl)-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 354, 100% @ rt = 4.52 mincarboxylic acid (4-methoxy-phenyl)- methyl-amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(2- [M + H]⁺ = 349, 100% @ rt =5.28 min methyl-2,3-dihydro-indol-1-yl)-methanone6-(3-Fluoro-phenyl)-pyrimidine-4- [M + H]⁺ = 294, 100% @ rt = 3.61 mincarboxylic acid pyridin-3-ylamide 6-(3-Chloro-phenyl)-pyrimidine-4- [M +H]⁺ = 389, 100% @ rt = 5.43 min carboxylic acid (2,2-difluoro-benzo[1,3]dioxol-5-yl)-amide [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(5-[M + H]⁺ = 354, 100% @ rt = 5.04 minfluoro-2,3-dihydro-indol-1-yl)-methanone(5-Chloro-2,3-dihydro-indol-1-yl)-[6-(3- [M + H]⁺ = 370, 100% @ rt =5.31 min chloro-phenyl)-pyrimidin-4-yl]-methanone6-(3,5-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 345, 97% @ rt = 4.56min carboxylic acid pyrimidin-5-ylamide6-(3-Chloro-4-trifluoromethyl-phenyl)- [M + H]⁺ = 316, 99% @ rt = 4.62min pyrimidine-4-carboxylic acid methyl ester6-(3-Chloro-4-trifluoromethyl-phenyl)- [M + H]⁺ = 302, 100% @ rt = 4.38min pyrimidine-4-carboxylic acid 6-(3-Chloro-4-trifluoromethyl-phenyl)-[M + H]⁺ = 379, 100% @ rt = 4.34 min pyrimidine-4-carboxylic acidpyridin-3- ylamide [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(2,3- [M + H]⁺ =337, 100% @ rt = 3.24 min dihydro-pyrrolo[3,2-c]pyridin-1-yl)- methanone6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 403, 100% @ rt = 4.85 mincarboxylic acid (2,2-difluoro- benzo[1,3]dioxol-5-yl)-methyl-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 316, 100% @ rt = 4.75 mincarboxylic acid thiazol-2-ylamide 6-(3-Chloro-phenyl)-pyrimidine-4- [M +H]⁺ = 314/316, 100% @ rt = 4.69 min carboxylic acid(3-methyl-isoxazol-5-yl)- amide 6-(3-Chloro-phenyl)-pyrimidine-4- [M +H]⁺ = 315/317, 100% @ rt = 3.92 min carboxylic acid(5-methyl-[1,3,4]oxadiazol- 2-yl)-amide6-(3-Chloro-phenyl)-pyrimidine-4- [M + H]⁺ = 300/302, 100% @ rt = 4.08min carboxylic acid oxazol-2-ylamide 6-(3-Chloro-phenyl)-pyrimidine-4-[M + H]⁺ = 331, 99% @ rt = 4.59 min carboxylic acid (3-methyl-[1,2,4]thiadiazol-5-yl)-amide 6-(3-Chloro-phenyl)-pyrimidine-4- LCMS notobtained carboxylic acid (4H-[1,2,4]triazol-3-yl)- amide6-(3,4-Difluoro-phenyl)-pyrimidine-4- [M + H]⁺ = 251, 100% @ rt = 4.11min carboxylic acid methyl ester6-(5-Chloro-2-fluoro-phenyl)-pyrimidine- [M + H]⁺ = 267, 100% @ rt =4.31 min 4-carboxylic acid methyl ester6-(3,4-Difluoro-phenyl)-pyrimidine-4- [M + H]⁺ = 236, 100% @ rt = 3.74min carboxylic acid 6-(3,4-Difluoro-phenyl)-pyrimidine-4- [M + H]⁺ =314, 98% @ rt = 4.09 min carboxylic acid pyrimidin-5-ylamide6-(5-Chloro-2-fluoro-phenyl)-pyrimidine- [M + H]⁺ = 253, 100% @ rt =3.64-3.93 min 4-carboxylic acid[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 395, 100% @ rt =5.69 min (1′,2′-dihydro-spiro[cyclopropane-1,3′-[3H]indol]-1′)-methanone 6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺= 374, 100% @ rt = 3.69 min carboxylic acid (2,6-dimethyl-pyridin-3-yl)-amide 6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 372, 100% @rt = 3.56 min carboxylic acid (2,6-dimethyl-pyridin-3- yl)-amidehydrochloride salt 6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 348,100% @ rt = 5.13 min carboxylic acid (3-methyl-isoxazol-5-yl)- amide6-(3-Chloro-4-fluoro-phenyl)-pyrimidine- [M + H]⁺ = 266, 100% @ rt =4.35 min 4-carboxylic acid methyl ester6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 350, 99% @ rt = 4.19min carboxylic acid (5-methyl-[1,3,4]oxadiazol- 2-yl)-amide6-(3-Chloro-4-methoxy-phenyl)- [M + H]⁺ = 279, 100% @ rt = 4.35 minpyrimidine-4-carboxylic acid methyl ester 6-(3-Chloro-4-methoxy-phenyl)-[M + H]⁺ = 264, 100% @ rt = 3.73-4.10 min pyrimidine-4-carboxylic acid6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 360, 100% @ rt = 3.46min carboxylic acid (pyridin-4-ylmethyl)-amide6-(3-Chloro-4-fluoro-phenyl)-pyrimidine- [M + H]⁺ = 292, 100% @ rt =3.92-4.23 min 4-carboxylic acid 6-(3,4-Dichloro-phenyl)-pyrimidine-4-[M + H]⁺ = 351, 100% @ rt = 4.42 min carboxylic acid[1,3,4]thiadiazol-2-ylamide 6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M +H]⁺ = 312, 96% @ rt = 3.18 min carboxylic acid (2-amino-ethyl)-amide(5-Chloro-2,3-dihydro-indol-1-yl)-[6-(3,4- [M + H]⁺ = 405, 100% @ rt =5.44 min dichloro-phenyl)-pyrimidin-4-yl]- methanone[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 387, 100% @ rt =5.46 min (5-fluoro-2,3-dihydro-indol-1-yl)- methanone[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 455, 100% @ rt =5.17 min (5-morpholin-4-yl-2,3-dihydro-indol-1-yl)- methanone6-(3,4-Dichloro-phenyl)-5-fluoro- [M + H]⁺ = 286, 100% @ rt = 3.85 minpyrimidine-4-carboxylic acid 6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M +H]⁺ = 346, 100% @ rt = 3.33 min carboxylic acid pyridin-4-ylamide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 344, 100% @ rt = 5.19min carboxylic acid pyridin-2-ylamide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 347, 98% @ rt = 4.40min carboxylic acid (1-methyl-1H-pyrazol-4- yl)-amide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 334, 100% @ rt = 4.68min carboxylic acid isoxazol-3-ylamide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 350, 100% @ rt = 4.87min carboxylic acid thiazol-2-ylamide[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 369, 100% @ rt =5.25 min (1,3-dihydro-isoindol-2-yl)-methanone6-(3,4-Dichloro-phenyl)-pyrimidine-4- LCMS not obtained carboxylic acid(4H-[1,2,4]triazol-3-yl)- amide 4-(3,4-Dichloro-phenyl)-6-(5-fluoro-[M + H]⁺ = 319, 100% @ rt = 5.41 min pyridin-2-yl)-pyrimidine6-(3,4-Difluoro-phenyl)-pyrimidine-4- [M + H]⁺ = 313, 100% @ rt = 3.82min carboxylic acid pyridin-3-ylamide6-(3-Trifluoromethyl-phenyl)-pyrimidine- [M + H]⁺ = 345, 100% @ rt =4.23 min 4-carboxylic acid pyrimidin-5-ylamide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 359, 100% @ rt = 4.47min carboxylic acid (2-methyl-pyrimidin-5-yl)- amide6-(3-Chloro-4-methyl-phenyl)-pyrimidine- [M + H]⁺ = 263, 99.8% @ rt =4.36 min 4-carboxylic acid methyl ester6-(3-Chloro-4-methyl-phenyl)-pyrimidine- [M + H]⁺ = 248, 100% @ rt =4.21 min 4-carboxylic acid 6-(3-Chloro-4-fluoro-phenyl)-pyrimidine- [M +H]⁺ = 328, 100% @ rt = 3.96 min 4-carboxylic acid pyridin-3-ylamide6-(3-Chloro-4-fluoro-phenyl)-pyrimidine- [M + H]⁺ = 358, 100% @ rt =3.27 min 4-carboxylic acid (2,6-dimethyl-pyridin-3- yl)-amide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 354, 100% @ rt = 3.83min carboxylic acid (2-acetylamino-ethyl)- amide6-(3,4-Dichloro-phenyl)-pyrimidine-4- [M + H]⁺ = 304, 99% @ rt = 3.88min sulfonate sodium salt [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]- [M +H]⁺ = 398, 100% @ rt = 5.45 min (3,3-dimethyl-2,3-dihydro-indol-1-yl)-methanone [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 352, 100%@ rt = 3.88 min (4-hydroxy-piperidin-1-yl)-methanone[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]- [M + H]⁺ = 337, 100% @ rt =4.21 min morpholin-4-yl-methanone6-(3-Chloro-4-fluoro-phenyl)-pyrimidine- [M + H]⁺ = 329, 100% @ rt =4.21 min 4-carboxylic acid pyrimidin-5-ylamide6-(3,4-Dichloro-phenyl)-5-fluoro- [M + H]⁺ = 302, 98% @ rt = 4.63 minpyrimidine-4-carboxylic acid methyl ester6-(3,4-Dichloro-phenyl)-5-fluoro- [M + H]⁺ = 286, 100% @ rt = 3.85 minpyrimidine-4-carboxylic acid 6-(3,4-Dichloro-phenyl)-5-fluoro- [M + H]⁺= 362, 99% @ rt = 4.07 min pyrimidine-4-carboxylic acid pyridin-3-ylamide 6-(3,4-Dichloro-phenyl)-5-fluoro- [M + H]⁺ = 391, 98% @ rt =3.51 min pyrimidine-4-carboxylic acid (2,6- dimethyl-pyridin-3-yl)-amide6-(3,4-Dichloro-phenyl)-5-fluoro- [M + H]⁺ = 363, 100% @ rt = 4.34 minpyrimidine-4-carboxylic acid pyrimidin-5- ylamide2-(3-Chloro-phenyl)-isonicotinic acid [M + H]⁺ = 248, 95% @ rt = 4.52min methyl ester 2-(3-Chloro-phenyl)-isonicotinic acid [M + H]⁺ =234/236, 100% @ rt = 3.95 min hydrochloride salt4-(3-Chloro-phenyl)-pyridine-2-carboxylic [M + H]⁺ = 234/530, 95% @ rt =4.26 min acid 4-(3-Chloro-phenyl)-pyridine-2-carboxylic [M + H]⁺ = 248,98% @ rt = 4.50 min acid methyl ester4-(3-Chloro-phenyl)-pyridine-2-carboxylic [M + H]⁺ = 310, 100% @ rt =4.12 min acid pyridin-3-ylamide4-(3-Chloro-phenyl)-pyridine-2-carboxylic [M + H]⁺ = 309, 100% @ rt =5.15 min acid phenylamide [4-(3-Chloro-phenyl)-pyridin-2-yl]-(2,3- [M +H]⁺ = 335, 100% @ rt = 4.91 min dihydro-indol-1-yl)-methanone4-(3-Chloro-phenyl)-pyridine-2-carboxylic [M + H]⁺ = 323, 100% @ rt =5.37 min acid p-tolylamide 4-(3-Chloro-phenyl)-pyridine-2-carboxylic[M + H]⁺ = 340, 99% @ rt = 4.32 min acid (5-methoxy-pyridin-3-yl)-amide4-(3,5-Dichloro-phenyl)-pyridine-2- [M + H]⁺ = 343, 100% @ rt = 5.47 mincarboxylic acid phenylamide 4-(3,5-Dichloro-phenyl)-pyridine-2- [M + H]⁺= 357, 100% @ rt = 5.65 min carboxylic acid p-tolylamide4-(3,5-Dichloro-phenyl)-pyridine-2- [M + H]⁺ = 345, 100% @ rt = 4.21 mincarboxylic acid pyridin-3-ylamide 4-(3,5-Dichloro-phenyl)-pyridine-2-[M + H]⁺ = 375, 100% @ rt = 4.72 min carboxylic acid(5-methoxy-pyridin-3-yl)- amide [4-(3,5-Dichloro-phenyl)-pyridin-2-yl]-[M + H]⁺ = 368, 100% @ rt = 5.42 min (2,3-dihydro-indol-1-yl)-methanone4-(3-Chloro-phenyl)-pyridine-2-carboxylic [M + H]⁺ = 310, 100% @ rt =4.23 min acid pyrimidin-5-ylamide 4-(3,4-Dichloro-phenyl)-pyridine-2-[M + H]⁺ = 342, 100% @ rt = 5.40 min carboxylic acid phenylamide4-(3,4-Dichloro-phenyl)-pyridine-2- [M + H]⁺ = 357, 100% @ rt = 5.59 mincarboxylic acid p-tolylamide 4-(3,4-Dichloro-phenyl)-pyridine-2- [M +H]⁺ = 344, 98% @ rt = 4.13 min carboxylic acid pyridin-3-ylamide[4-(3,4-Dichloro-phenyl)-pyridin-2-yl]- [M + H]⁺ = 369, 100% @ rt = 5.14min (2,3-dihydro-indol-1-yl)-methanone4-(3,4-Dichloro-phenyl)-pyridine-2- [M + H]⁺ = 374, 375.7, 100% @ rt =4.66 min carboxylic acid (5-methoxy-pyridin-3-yl)- amide4-(3,4-Dichloro-phenyl)-pyridine-2- [M + H]⁺ = 268, 98% @ rt = 4.26 mincarboxylic acid hydrochloride salt 4-(3,4-Dichloro-phenyl)-pyridine-2-[M + H]⁺ = 344, 100% @ rt = 4.56 min carboxylic acid pyrimidin-5-ylamide4-(3,5-Dichloro-phenyl)-pyridine-2- [M + H]⁺ not observed; poorcarboxylic acid hydrocloride salt ionisation4-(3,5-Dichloro-phenyl)-pyridine-2- [M + H]⁺ = 344, 100% @ rt = 4.67 mincarboxylic acid pyrimidin-5-ylamide5-Morpholin-4-yl-pyridine-2-carboxylic [M + H]⁺ = 265, 98% @ rt = 3.50min acid tert-butyl ester

Example 12

A generalized procedure for monitoring L-Kynurenine (KYN) hydroxylationto form product 3-Hydroxy-Kynurenine (3OH-KYN) by LC/MS is describedbelow. Product is quantified by multiple reaction monitoring using MS.

Key Reagents:

-   Compound: Stock concentrations: 10 mM in 100% DMSO-   Cell line: CHO GST HIS KMO cell line, 1E4 cells/well/100 μl in    96well cell plate-   Substrate: L-Kynurenine (Sigma: Cat#K3750, stock concentration: 10    mM in 100 mM potassium phosphate buffer, pH 7.4)    Assay Conditions:-   Medium: OptiMem (Reduced Serum Medium 1x, +L-Glutamine+HEPES—Phenol    Red; GIBCO: Cat# 11058)-   Assay Volume: 200 μl-   Plate Format: 96 well plate, transparent (Corning)-   Read-Out: product (3OH-KYN) quantification using product specific    MRM-   Reader: LC/MS/MS    Assay Protocol:    -   prepare serial dilution (factor 3) of compound in 100% DMSO (top        concentration=6.67 mM, 100% DMSO)        -   [8 points: 6.67 mM; 2.22 mM; 0.74 mM; 0.247 mM; 0.082 mM;            0.027 mM; 0.009 mM; 0.003 mM]    -   prepare 300-fold concentrated solution of each compound        concentration (top concentration 22.22 μM, 0.3% DMSO) in OptiMem        medium        -   [22.2 μM; 7.41 μM; 2.47 μM; 0.82 μM; 0.27 μM; 0.09 μM; 0.03            μM; 0.01 μM]    -   prepare substrate (10 mM) at concentration of 1.1 mM in medium    -   medium of cell plate is drawed off    -   cells are washed with OptiMem (100 μl/well) and drawed off again    -   assay mix: 90 μl OptiMem/well+90 μl compound/well of each        concentration        -   [final compound top concentration: 10 μM; 0.15% DMSO]        -   [final compound bottom concentration: 0.004 μM; 0.15% DMSO]    -   pre-incubation: 30 min at 37° C.    -   add 20 μl/well of the 1.1 mM substrate solution (final assay        concentration: 100 μM)    -   positive control: 200 μl OptiMem    -   negative control: 180 μl OptiMem+20 μl 1.1 mM substrate    -   incubate ˜24 h at 37° C.    -   transfer 100 μl of each well in a transparent 96well plate        (Corning)    -   add 100 μl/well 10% trichloro acetic acid (TCA) in water    -   centrifugate plate for 3 min at 4000 rpm    -   detect product by LC/MS (injection of 50 μl/well; 2.5 fold        overfill of the 20 μl sample loop)        Data Analysis: IC₅₀'s are calculated using automated fitting        algorithm (A+Analysis).

Example 13

A method of monitoring L-Kynurenine (KYN) hydroxylation to form product3-Hydroxy-Kynurenine (3OH-KYN) by LC/MS is described below. Product isquantified by multiple reaction monitoring.

Key Reagents:

-   Compound: Stock concentrations: 10 mM in 100% DMSO-   Enzyme: KMO enzyme prepared at Evotec via mitochondria isolation    from CHO-GST HIS KMO cells-   Substrate: L-Kynurenine (Sigma: Cat# K3750)    -   [stock concentration: 10 mM in 100 mM potassium phosphate        buffer, pH 7.4]        Assay Conditions:-   Buffer: 100 mM potassium phosphate, pH 7.4, 200 μM NADPH, 0.4 U/ml    G6P-DH (Glucose 6-phosphate dehydrogenase), 3 mM G6P (D-Glucose    6-phosphate)-   Assay Volume: 40 μl-   Plate Format: 384 well plate, transparent (Matrix)-   Read-Out: product (3OH-KYN) quantification using product specific    MRM-   Reader: LC/MS/MS    Assay Protocol:    -   prepare serial dilution (factor 3)of compound in 100% DMSO (top        concentration=10 mM, 100% DMSO)        -   [8 points: 10 mM; 3.33 mM; 1.11 mM; 0.37 mM; 0.12 mM; 0.04            mM; 0.0137 mM; 0.0045 mM, 0.0015 mM]    -   prepare 3.33-fold concentrated solution of each compound        concentration (top concentration 300 μM, 3% DMSO) in assay        buffer        -   [concentrations: 300 μM; 100 μM; 33.3 μM; 11.1 μM; 3.70 μM;            1.23 μM; 0.41 μM; 0.137 μM]    -   prepare substrate (10 mM) at concentration of 1 mM in assay        buffer    -   assay mix: 4 μl compound/well of each concentration+24 μl assay        buffer/well+8 μl KMO human enzyme+4 μl 1 mM substrate (final        concentration=100 μM)        -   [final compound top concentration: 30 μM; 0.3% DMSO]        -   [final compound bottom concentration: 0.0137 μM; 0.3% DMSO]    -   positive control: 4 μl 50 μM FCE28833 in assay buffer [0.5%        DMSO] (final assay concentration=5 μM)+24 μl assay buffer/well+8        μl KMO human enzyme+1 mM substrate (final concentration=100 μM)    -   negative control: 28 μl assay buffer/well+8 μl KMO human        enzyme+4 μl 1 mM substrate (final concentration=100 μM)    -   incubate 400 min at RT    -   add 40 μl/well 10% trichloro acetic acid in water to stop the        assay and precipitate protein    -   centrifuge plate for 3 min at 4000 rpm    -   product detection by LC/MS (injection of 50 μl/well; 2.5 fold        overfill of the 20 μl sample loop)        Data Analysis: IC₅₀'s are calculated using automated fitting        algorithm (A+Analysis).

Example 14

A method of monitoring L-Kynurenine (KYN) hydroxylation to form3-Hydroxy-Kynurenine (3OH-KYN) by LC/MS is described. Product isquantified by multiple reaction monitoring (MRM method).

Key Reagents:

-   Compound: Stock concentrations: 10 mM in 100% DMSO-   Enzyme: KMO enzyme prepared at Evotec from mouse liver (4-6 weeks    old) via mitochondria isolation as described in the literature-   Substrate: L-Kynurenine (Sigma: Cat# K3750, stock concentration: 10    mM in 100 mM potassium phosphate buffer, pH 7.4)    Assay Conditions:

Buffer: 100 mM potassium phosphate, pH 7.4, 200 μM NADPH, 0.4 U/mlG6P-DH (Glucose 6-phosphate Dehydrogenase), 3 mM G6P (D-Glucose6-phosphate)

-   Assay Volume: 40 μl-   Plate Format: 384 well plate, transparent (Matrix)-   Read-Out: product (3OH-KYN) quantification using product specific    MRM-   Reader: LC/MS/MS    Assay Protocol:    -   prepare serial dilution (factor 3)of compound in 100% DMSO (top        concentration=10 mM, 100% DMSO)        -   [8 points: 10 mM; 3.33 mM; 1.11 mM; 0.37 mM; 0.12 mM; 0.04            mM; 0.0137 mM; 0.0045 mM, 0.0015 mM]    -   prepare 3.33-fold concentrated solution of each compound        concentration (top concentration 300 μM, 3% DMSO)in assay buffer        -   [concentrations: 300 μM; 100 μM; 33.3 μM; 11.1 μM; 3.70 μM;            1.23 μM; 0.41 μM; 0.137 μM]    -   prepare substrate (10 mM) at concentration of 1 mM in assay        buffer    -   assay mix: 4 μl compound/well of each concentration+24 μl        assaybuffer/well+8 μl KMO mouse enzyme+4 μl 1 mM substrate        (final concentration=100 μM)        -   [final compound top concentration: 30 μM; 0.3% DMSO]        -   [final compound bottom concentration: 0.0137 μM; 0.3% DMSO]    -   positive control: 4 μl 50 μM FCE28833 in assay buffer, 0.5% DMSO        [final assay concentration=5 μM]+24 μl assay buffer/well+8 μl        KMO mouse enzyme+4 μl 1 mM substrate [final concentration=100        μM]    -   negative control: 28 μl assay buffer/well+8 μl KMO mouse        enzyme+4 μl 1 mM substrate [final concentration=100 μM]    -   incubate 40 min at RT    -   add 40 μl/well 10% trichloro acetic acid in water to stop the        assay and precipitate protein    -   centrifuge plate for 3 min at 4000 rpm    -   product detection by LC/MS (injection of 20 μl/well, 2 fold        overfill of the 10 μl sample loop)        Data analysis: IC₅₀'s are calculated using automated fitting        algorithm (A+Analysis).

Example 15

Using procedures similar to those described herein, the followingcompounds were assayed for activity.

INH.Mouse @ IUPAC name 10 μM6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid methyl ester 101.46-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid methyl ester 105.66-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid methyl ester 101.26-(3,4-Dichloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid methyl95.5 ester 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid 105.56-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid 105.66-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid 102.16-(3,4-Dichloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid 102.56-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-3-ylamide83.5 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-3-ylamide98.6 N-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-3,4-dimethoxy- 85.0benzenesulfonamideN-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-methanesulfonamide 51.26-(3-chloro-phenyl)-pyrimidine-4-carboxylic acid sodium salt 100.06-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid cyclohexyl ammonium100.0 salt 6-(3,4-dichloro-phenyl)-pyrimidine-4-carboxylic acid sodiumsalt 100.0 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acidpyrimidin-5-ylamide 100.06-(4-Fluoro-3-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid 92.7methyl ester 6-(3-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acidmethyl ester 94.56-(4-Fluoro-3-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid 94.86-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-3-ylamide72.2 6-(3-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid 77.76-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid ethylamide 100.06-(5-Fluoro-pyridin-3-yl)-pyrimidine-4-carboxylic acid 96.16-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid amide 77.56-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid methylamide 100.06-(5-Fluoro-pyridin-3-yl)-pyrimidine-4-carboxylic acid methyl ester 87.26-(3-Fluoro-5-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid 75.86-(5-Chloro-pyridin-3-yl)-pyrimidine-4-carboxylic acid methyl ester 93.26-(5-Chloro-pyridin-3-yl)-pyrimidine-4-carboxylic acid 91.76-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid isopropylamide 100.0[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-morpholin-4-yl-methanone 100.06-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid propylamide 72.46-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid phenylamide 100.06-Pyridin-3-yl-pyrimidine-4-carboxylic acid methyl ester trifluoroacetic74.5 acid salt 6-Phenyl-pyrimidine-4-carboxylic acid 100.06-(2-Fluoro-5-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid 80.36-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid o-tolylamide 96.26-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid p-tolylamide 100.0[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(3,4-dihydro-2H-quinolin-1-yl)-100.0 methanone 6-Phenyl-pyrimidine-4-carboxylic acid methyl ester 100.06-(2,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid methyl ester 100.06-(2,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid 100.06-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (6-methoxy-pyridin-3-93.4 yl)-amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(2,3-dihydro-indol-1-yl)-methanone100.0 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid m-tolylamide 96.66-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid methyl-pyridin-3-yl-95.2 amide 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid(5-methoxy-pyridin-3- 100.0 yl)-amide6-(3-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid methyl ester100.0 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid dimethylamide100.0 6-(3-Chloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid methylester 100.04-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-piperazin-2-one 100.06-(3-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid 100.06-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (4-methoxy-pyridin-3-91.0 yl)-amide 6-(3-Chloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid100.0 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid(2-hydroxy-ethyl)- 95.8 amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(4-hydroxy-piperidin-1-yl)- 100.0methanone 6-(3-Methoxy-phenyl)-pyrimidine-4-carboxylic acid 81.06-(3-Methoxy-phenyl)-pyrimidine-4-carboxylic acid methyl ester 77.56-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid benzylamide 67.0[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(4-methyl-piperazin-1-yl)- 64.3methanone [6-(3-Chloro-phenyl)-pyrimidin-4-yl]-pyrrolidin-1-yl-methanone90.5 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid ((S)-2-hydroxy-87.3 propyl)-amide 6-m-Tolyl-pyrimidine-4-carboxylic acid methyl ester96.3 1-{4-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-piperazin-1-yl}-94.9 ethanone 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid((R)-2-hydroxy- 74.3 propyl)-amide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (2-methoxy-phenyl)-100.0 amide 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid(4-methoxy-phenyl)- 100.0 amide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (3-methoxy-phenyl)-97.1 amide Sodium; 6-(3-chloro-phenyl)-pyrimidine-4-sulfonate 97.16-m-Tolyl-pyrimidine-4-carboxylic acid 97.96-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid methyl-phenyl-amide100.0 [6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(2,3-dihydro-indol-1-yl)-100.0 methanoneN-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-methanesulfonamide 99.56-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-2-ylamide 100.06-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-4-ylamide 100.06-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (pyridin-4-ylmethyl)-100.0 amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(4-methyl-piperidin-1-yl)- 88.2methanone[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-((R)-3-hydroxy-pyrrolidin-1-yl)-83.9 methanone 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid[1,3,4]thiadiazol-2- 97.4 ylamide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid isoxazol-3-ylamide100.0 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid((R)-1-phenyl-ethyl)- 99.2 amide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid ((S)-1-phenyl-ethyl)-99.8 amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-((S)-3-hydroxy-pyrrolidin-1-yl)-84.9 methanone6-(3-Chloro-phenyl)-pyrimidine-4-carboxylicacid[4-(4-methyl-piperazin-87.7 1-yl)-phenyl]-amide 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylicacid (6-trifluoromethyl- 89.1 pyridin-3-yl)-amide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (pyridin-3-ylmethyl)-96.7 amide 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acidpyridazin-3-ylamide 100.0 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylicacid pyrazin-2-ylamide 100.0 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylicacid (4-morpholin-4-yl- 93.6 phenyl)-amide(S)-1-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-pyrrolidine-2- 91.1carboxylic acid amide(R)-1-[6-(3-Chloro-phenyl)-pyrimidine-4-carbonyl]-pyrrolidine-2- 95.4carboxylic acid amideAzetidin-1-yl-[6-(3-chloro-phenyl)-pyrimidin-4-yl]-methanone 100.06-(4-Methoxy-phenyl)-pyrimidine-4-carboxylic acid 100.0[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(1,3-dihydro-isoindol-2-yl)- 100.0methanone 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid(3,5-dimethyl- 79.0 isoxazol-4-yl)-amide[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(3,4-dihydro-2H-quinolin-1-yl)-92.6 methanone 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acidphenylamide 100.0 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acidp-tolylamide 100.0 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid(5-methoxy- 100.0 pyridin-3-yl)-amide6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid pyrimidin-5- 95.5ylamide 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid(6-methyl-pyridin- 100.0 3-yl)-amide6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid (6-methyl-pyridin-94.0 3-yl)-amide hydrochloride salt6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid (2-methyl-pyridin-84.2 3-yl)-amide 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acidpyrimidin-2-ylamide 100.0 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylicacid methyl-p-tolyl-amide 100.06-(3-Fluoro-phenyl)-pyrimidine-4-carboxylic acid methyl ester 100.06-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (6-methyl-pyridin-3-85.3 yl)-amide 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid(2-methyl-pyridin-3- 97.8 yl)-amide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (4-fluoro-phenyl)- 98.9amide 6-(3-Fluoro-phenyl)-pyrimidine-4-carboxylic acid 100.06-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid phenylamide 77.6[6-(3,5-Dichloro-phenyl)-pyrimidin-4-yl]-(2,3-dihydro-indol-1-yl)- 98.3methanone 6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid(5-methoxy- 54.8 pyridin-3-yl)-amide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (1-methyl-1H-pyrazol-100.0 3-yl)-amide 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid(1-methyl-1H-pyrazol- 100.0 4-yl)-amide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (4-methoxy-phenyl)-100.0 methyl-amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(2-methyl-2,3-dihydro-indol-1-yl)-76.9 methanone 6-(3-Fluoro-phenyl)-pyrimidine-4-carboxylic acidpyridin-3-ylamide 94.8 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid(2,2-difluoro- 97.7 benzo[1,3]dioxol-5-yl)-amide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(5-fluoro-2,3-dihydro-indol-1-yl)-100.0 methanone(5-Chloro-2,3-dihydro-indol-1-yl)-[6-(3-chloro-phenyl)-pyrimidin-4-yl]-100.0 methanone6-(3-Chloro-4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid 100.0methyl ester6-(3-Chloro-4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid 100.06-(3-Chloro-4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid 48.3pyridin-3-ylamide[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-(2,3-dihydro-pyrrolo[3,2-c]pyridin-100.0 1-yl)-methanone 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid(2,2-difluoro- 98.7 benzo[1,3]dioxol-5-yl)-methyl-amide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid thiazol-2-ylamide 100.06-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (3-methyl-isoxazol-5-100.0 yl)-amide 6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid(5-methyl- 100.0 [1,3,4]oxadiazol-2-yl)-amide6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid oxazol-2-ylamide 100.06-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid (3-methyl- 85.4[1,2,4]thiadiazol-5-yl)-amide6-(3,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid methyl ester 100.06-(5-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid methyl ester100.0 6-(3,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid 100.06-(3,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid pyrimidin-5- 100.0ylamide 6-(5-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid 100.0[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(1′,2′-dihydro- 100.0spiro[cyclopropane-1,3′-[3H]indol]-1′)-methanone6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid (2,6-dimethyl- 96.8pyridin-3-yl)-amide 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid(3-methyl- 100.0 isoxazol-5-yl)-amide6-(3-Chloro-4-fluoro-phenyl)-pyrimidine-4-carboxylic acid methyl ester100.0 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid (5-methyl-100.0 [1,3,4]oxadiazol-2-yl)-amide6-(3-Chloro-4-methoxy-phenyl)-pyrimidine-4-carboxylic acid methyl 100.0ester 6-(3-Chloro-4-methoxy-phenyl)-pyrimidine-4-carboxylic acid 100.06-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid (pyridin-4- 95.5ylmethyl)-amide 6-(3-Chloro-4-fluoro-phenyl)-pyrimidine-4-carboxylicacid 100.0 6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acidmethyl 100.0 ester 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid[1,3,4]thiadiazol-2- 100.0 ylamide(5-Chloro-2,3-dihydro-indol-1-yl)-[6-(3,4-dichloro-phenyl)-pyrimidin-4-100.0 yl]-methanone[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(5-fluoro-2,3-dihydro-indol-1-100.0 yl)-methanone6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acid 100.06-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid pyridin-4-ylamide90.1 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acidpyridin-2-ylamide 100.0 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylicacid (1-methyl-1H- 100.0 pyrazol-4-yl)-amide6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid isoxazol-3-ylamide100.0 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acidthiazol-2-ylamide 83.7[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-(1,3-dihydro-isoindol-2-yl)-63.5 methanone 6-(3,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acidpyridin-3-ylamide 84.7 6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylicacid (2-methyl- 85.6 pyrimidin-5-yl)-amide2-(3-Chloro-phenyl)-isonicotinic acid hydrochloride salt 53.54-(3-Chloro-phenyl)-pyridine-2-carboxylic acid 100.04-(3-Chloro-phenyl)-pyridine-2-carboxylic acid methyl ester 100.04-(3-Chloro-phenyl)-pyridine-2-carboxylic acid pyridin-3-ylamide 52.34-(3-Chloro-phenyl)-pyridine-2-carboxylic acid phenylamide 68.4[4-(3-Chloro-phenyl)-pyridin-2-yl]-(2,3-dihydro-indol-1-yl)-methanone100.0 4-(3-Chloro-phenyl)-pyridine-2-carboxylic acid p-tolylamide 85.64-(3-Chloro-phenyl)-pyridine-2-carboxylic acid (5-methoxy-pyridin-3-53.8 yl)-amide 4-(3,5-Dichloro-phenyl)-pyridine-2-carboxylic acidphenylamide 59.7 4-(3,5-Dichloro-phenyl)-pyridine-2-carboxylic acid(5-methoxy-pyridin- 52.6 3-yl)-amide[4-(3,5-Dichloro-phenyl)-pyridin-2-yl]-(2,3-dihydro-indol-1-yl)- 54.5methanone 4-(3-Chloro-phenyl)-pyridine-2-carboxylic acidpyrimidin-5-ylamide 60.8 4-(3,4-Dichloro-phenyl)-pyridine-2-carboxylicacid phenylamide 43.5[4-(3,4-Dichloro-phenyl)-pyridin-2-yl]-(2,3-dihydro-indol-1-yl)- 96.6methanone 4-(3,4-Dichloro-phenyl)-pyridine-2-carboxylic acidhydrochloride salt 100.0 4-(3,5-Dichloro-phenyl)-pyridine-2-carboxylicacid hydrocloride salt 76.6

While some embodiments have been shown and described, variousmodifications and substitutions may be made thereto without departingfrom the spirit and scope of the invention. For example, for claimconstruction purposes, it is not intended that the claims set forthhereinafter be construed in any way narrower than the literal languagethereof, and it is thus not intended that exemplary embodiments from thespecification be read into the claims. Accordingly, it is to beunderstood that the present invention has been described by way ofillustration and not limitations on the scope of the claims.

What is claimed:
 1. A method of treatment of a condition or disordermediated by Kynurenine 3-monooxygenase activity wherein the condition ordisorder is Huntington's disease, Alzheimer's disease, or Parkinson'sdisease in a subject in need of such treatment, comprising administeringto the subject a therapeutically effective amount of a compound ofFormula I

or a pharmaceutically acceptable salt thereof wherein: X and Y are N; R₁is chosen from aryl and heteroaryl, each of which is optionallysubstituted with one, two, or three groups chosen from halo, optionallysubstituted lower alkyl, lower alkoxy, optionally substituted amino,optionally substituted heterocycloalkyl, optionally substitutedheteroaryl, and hydroxy; L is —C(O)O—; R₂ is hydrogen; R₄ is chosen fromhydrogen and optionally substituted lower alkyl; and R₅ is chosen fromhydrogen and fluoro.
 2. The method of claim 1 wherein R₁ is phenyloptionally substituted with one, two, or three groups chosen from halo,optionally substituted lower alkyl, optionally substituted lower alkoxy,and hydroxy.
 3. The method of claim 2 wherein R₁ is phenyl optionallysubstituted with one, two, or three groups chosen from halo, loweralkyl, trifluoromethyl, lower alkoxy, and hydroxy.
 4. The method ofclaim 3 wherein R₁ is phenyl optionally substituted with one, two, orthree groups chosen from halo, lower alkyl, and trifluoromethyl.
 5. Themethod of claim 4 wherein R₁ is chosen from 2-trifluoromethylphenyl,3,4-dichlorophenyl, 3-chlorophenyl, 4-chlorophenyl, and3,5-dichlorophenyl.
 6. The method of claim 1 wherein R₄ is hydrogen. 7.The method of claim 1 wherein R₅ is hydrogen.
 8. A method of treatmentof a condition or disorder mediated by Kynurenine 3-monooxygenaseactivity, wherein the condition or disorder is Huntington's disease,Alzheimer's disease, or Parkinson's disease, in a subject in need ofsuch treatment, comprising administering to the subject atherapeutically effective amount of a compound chosen from:6-(2-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;6-(3-Chloro-phenyl)-pyrimidine-4-carboxylic acid;6-(3,4-Dichloro-phenyl)-pyrimidine-4-carboxylic acid;6-(3,5-Dichloro-phenyl)-pyrimidine-4-carboxylic acid; 6-(3,4-Dichloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid;6-(4-Fluoro-3-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;6-(3-Trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;6-(5-Fluoro-pyridin-3-yl)-pyrimidine-4-carboxylic acid;6-(3-Fluoro-5-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;6-(5-Chloro-pyridin-3-yl)-pyrimidine-4-carboxylic acid;6-Phenyl-pyrimidine-4-carboxylic acid;6-(2-Fluoro-5-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;6-(2,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid;6-(3-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid;6-(3-Chloro-phenyl)-2-methyl-pyrimidine-4-carboxylic acid;6-(3-Methoxy-phenyl)-pyrimidine-4-carboxylic acid;6-m-Tolyl-pyrimidine-4-carboxylic acid;6-(4-Methoxy-phenyl)-pyrimidine-4-carboxylic acid;6-(3-Fluoro-phenyl)-pyrimidine-4-carboxylic acid;6-(3-Chloro-4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid;6-(3,4-Difluoro-phenyl)-pyrimidine-4-carboxylic acid;6-(5-Chloro-2-fluoro-phenyl)-pyrimidine-4-carboxylic acid;6-(3-Chloro-4-methoxy-phenyl)-pyrimidine-4-carboxylic acid;6-(3-Chloro-4-fluoro-phenyl)-pyrimidine-4-carboxylic acid;6-(3,4-Dichloro-phenyl}-5-fluoro-pyrimidine-4-carboxylic acid;6-(3-Chloro-4-methyl-phenyl)-pyrimidine-4-carboxylic acid; and6-(3,4-Dichloro-phenyl)-5-fluoro-pyrimidine-4-carboxylic acid; or athereof.
 9. The method according to claim 1 wherein the condition ordisorder mediated by Kynurenine 3-monooxygenase activity is Huntington'sdisease.